

A

- Abdominal wall defect, 266, 284
 ABO grouping, 422–423, 429
 forward, 422
 reverse, 422
 Abortion, spontaneous, 283, 285, 290, 305
 Abscess, 484. *See also specific sites*
 diagnosis of infectious disease, 482
 Absolute RBC count, 326
 Acanthocytes, 353
 Acetaminophen, 224, 228, **258**
 Acetone, **247**
 Acetylcholinesterase, 285
 N-Acetylprocainamide, **258**
 Achlorhydria, 200–202
 Acid-base balance, 26, 33–39
 Acid-base disorders, **38**
 metabolic, 38–39
 respiratory, 39
 urine pH, **73**
 Acid elution test, 430
 Acid-fast stains, 485–486
 α_1 -Acid glycoprotein, 129
 Acidosis, 28
 diabetic, **361**
 lactic, 82
 metabolic, 29, 37–39, **38, 73**
 respiratory, 37, **38, 39, 73**
 Acid phosphatase, tartrate-resistant, **53**
 ACLAT syndrome. *See* Anticardiolipin antibody-thrombosis syndrome
 Acridine orange stain, 486
 Acromegaly, 176, 185
 Acrosome reaction, 543
 ACTH. *See* Adrenocorticotropin
 Activated partial thromboplastin time (aPTT), 405
 Activated protein C (APC) resistance, 407, **407, 409–411**
 Activated prothrombin complex concentrate, 442
 Acute coronary syndrome, 236–237
 Acute-phase reactant, 233–234
 Acute tubular necrosis, 86
 Addison disease, **450**
 Adenosine deaminase
 CSF, 102
 peritoneal effusion, 116
 serous effusions, 110
 Adenovirus, 478–479, **493, 495**
 ADH. *See* Antidiuretic hormone
 Adrenal adenoma, 164, 166–167
 Adrenal cancer, 164, 166, 192, **263**
 Adrenal cortex, 162
 Adrenal dysfunction, **547**
 Adrenal gland function, 161–169
 adrenocortical insufficiency, 163–164
 background, 162
 Cushing's syndrome, 164–166
 pheochromocytoma, 168
 primary hyperaldosteronism, 166–167
 Adrenal hemorrhage, 163
 Adrenal hyperplasia, 167, 534
 Adrenal medulla, 162
 Adrenocortical insufficiency, 28, 49, **68, 163–164, 191, 369**
 Adrenocorticotropin (ACTH), 162, 164–165, 168, 172–173, **172**
 “big,” 166
 deficiency, 174
 Adrenocorticotropin (ACTH) stimulation test, 163
 Adrenogenital syndrome, 167–168
 Adrenoleukodystrophy, 136
 Afibrinogenemia, 391–392
 AFP. *See* Alpha-fetoprotein
 Agammaglobulinemia, X-linked, **459, 461, 462**
 Agar dilution method, antimicrobial susceptibility testing, 488
 Agranulocytosis, 363–364, **466**
 AIDS. *See* HIV disease
 Alanine aminotransferase (ALT)
 donor blood, 434
 serum, 225
 Albumin, 124, **128**
 blood, 47–48
 liver function test, 224
 serum protein electrophoresis, 129
 urine, 76–77, 189
 Albumin index, 136
 Albuminocytologic dissociation, 100
 Albumin/plasma protein fraction, 441
 Alcoholism, 28, **144, 165, 228, 327, 338**
 Alcohol withdrawal, 52
 Aldosterone, **68, 162, 166–167**
 Algorithm. *See* Decision tree
 Alkali ingestion, 38
 Alkaline nitroprusside test, ketonuria, 82
 Alkaline phosphatase (ALP), **53**
 age-related reference ranges, 532, **533**
 blood, 48–49, 226–228, **227**
 bone, 275–276
 liver, 275–276
 placental, 276
 as tumor marker, **263, 275–276**
 Alkaline picrate chromogenic assay, creatinine, 60
 Alkaline tide, **73**
 Alkalosis, 28
 hypokalemic, 166–167
 metabolic, 29, **32, 37–38, 38, 73, 73**
 respiratory, 37, **38, 39, 73**
 Allergy, **366–367, 367**
 ALP. *See* Alkaline phosphatase
 Alpha-fetoprotein (AFP)
 amniotic fluid, 284
 liver function tests, 233
 maternal serum, 266, 282, **283, 284, 288, 306**
 peritoneal effusion, 115
 serous effusions, 111
 serum protein electrophoresis, 129
 as tumor marker, 111, **263, 265–266**
 Alprazolam, **259**
 ALT. *See* Alanine aminotransferase
 AMA. *See* Antimitochondrial antibodies
 Amebiasis, 508
 Amikacin, **258**
 Amino acids
 serum, 299
 urine, 299
 Aminopyrine, **364**
 Amiodarone, 157, **258**
 Amitriptyline, **259**
 Amniocentesis, 311
 Amniostat-FLM, 292
 Amniotic fluid
 alpha-fetoprotein, 284
 cytogenetic studies, 311
 surfactant, 286, **287, 291–292**
 Amoxapine, **259**
 Amphetamines, 248

- Ampholytes, 127
- Amylase
peritoneal effusion, 115
serous effusions, 110
serum, 203–204, 206, 208
urine, 204, 207
- Amylase clearance, 204
- Amyloidosis, 76, 226, 382, 399
- Analytical error, 20–21
- ANCA. *See* Antineutrophil cytoplasmic antibody
- Anemia, 326. *See also specific types of anemia*
bone marrow examination, **342**
of chronic disease, **327**, 328, **331**, 333, **334**, 343
classification, 326, **327**
due to accelerated RBC destruction, 344–354
due to blood loss, 331–332, **331**
due to impaired RBC production, 332–343
macrocytic, **327**, **339**
megaloblastic, 336–338, **337**, **364**
microcytic, **327**, 333–335, **334–336**
normochromic/normocytic, **327**
normocytic, **341**
of renal failure, **327**, 343
reticulocyte counts, **331**
- Anesthetic agents, 363
- Aneuploidy, **304**
- Angelman syndrome, 306
- Angina, unstable, 236–237
- Anion gap, 30–31, **32–33**, **36**, 38–39
toxins causing increased, **247**
- Aniridia, 306
- Ankylosing spondylitis, **117**
- Anorexia, **547**
- Anorexia nervosa, 28
- Anovulation, 546, **547**
- Antacids, 52
- Anticardiolipin antibodies, 416, **469**
- Anticardiolipin antibody-thrombosis (ACLAT) syndrome, 416
- Anti-centromeric antibodies, **449**
- Anti-CHO test, 506
- Anticoagulants, 397, 398, 417
- Anticonvulsants, 49, 165, 256–257
- Antideoxyribonuclease B antibody test, streptococcal disease, 505
- Antidiuretic hormone (ADH), 64, 74
disorders of secretion, 178–180
- Antimicrobial susceptibility testing, 487–488
- Antimitochondrial antibodies (AMA), 232
- Antineutrophil cytoplasmic antibody (ANCA)
A-ANCA/X-ANCA, **455**
assay, 454, **455–456**
C-ANCA, 454, **456**
P-ANCA, 454, **456**
- Antinuclear antibodies, 448–450, **449**, **456**
- Antiphospholipid syndrome, **407**
- Antiphospholipid-thrombosis syndrome, 416
- Antipreabsorption antigen test, poststreptococcal disease, 506
- Anti-Sm antibodies, **449**, 452
- Antisperm antibodies, 544, 546–547
- Anti-SS-A(Ro) antibodies, **449**, 452
- Anti-SS-B(La) antibodies, **449**, 452
- Antistreptolysin O (ASO) tests, 505
- Antithrombin, 398, 406, 413
acquired deficiency, 414
defects, **407**
hereditary deficiency, 413–414
- α_1 -Antitrypsin, **128**, 129, 398
deficiency, 134
liver function test, 233
- Anti-U1-RNP antibodies, **449**, 452
- Antral G cell hyperplasia/hypersensitivity, 202
- APC resistance. *See* Activated protein C resistance
- Apheresis platelets, 439
- Aplastic anemia, 308, **327**, **331**, 340–342, **340**, **368**, **466**
- Apoprotein A-I, 145, 149
- Apoprotein B, 147, 149
- Apoprotein B-100, 141, 144
- Apoprotein C-II, 140
deficiency, **141**
- Apoprotein E, 147
- aPTT. *See* Activated partial thromboplastin time
- Area-under-the-curve, 17, **18**
- Arsine, 353
- Arterial thrombosis, 416
- Arthritis, **117**, 119
- Arthrocentesis, 116
- Arthropathy, neuropathic, **117**
- Arthroscopy, **407**
- Ascites. *See* Peritoneal effusion
- ASO tests. *See* Antistreptolysin O tests
- L-Asparaginase, 412, 414
- Aspartate aminotransferase (AST), serum, 225
- Aspergillus*, 521
- AST. *See* Aspartate aminotransferase
- Asthenospermia, 540
- Asthma, bronchial, 99
- Ataxia telangiectasia, **459**
- Atelectasis, **106**
- Atherosclerosis, **407**
- Atomic absorption spectrometry, metal analysis, 252
- Autoimmune disease, 447–456
antibodies detected in, **449–450**
antibody to dsDNA, **449**, 452
antibody to extractable nuclear antigens, 452
antineutrophil cytoplasmic antibody assay, 454, **455–456**
background, 447
complement fractions, 453–454
diagnostic algorithm, **451**
immunofluorescent antinuclear antibody test, 448–450
organ-specific, **450**
rheumatoid factors, 453
- Autologous blood, 444
- Azoospermia, 539, **542**

B

- Babesiosis, 353
- Bacteremia, 473–474
- Bacteria
CSF, 103
serous effusions, 111
urine, 89–90
- Bacterial infections
immunologic tests, 500–506
molecular diagnostics, 519–520
- Bacterial overgrowth, 211, 213–216
choly-¹⁴C-glycine breath test, 213
hydrogen breath test, 213
jejunal culture, 214
¹⁴C-D-xylose breath test, 214
- Bacteriuria, **72**, 82, 89–90
- Barbiturates, 248, 257
- Bare lymphocyte syndrome, **459**
- Bartonella henselae*, 520

- Base excess, 36, **36**
 Basopenia, **358**, 367, **367**
 Basophil(s), 366–367
 Basophilia, **358**, 367, **367**
 Bauer-Kirby test, 488
 B-cell gene rearrangements, 322
 Bence-Jones protein, 77, 126, 133, 262, **263**, 264, 383
 Benedict's test, 79
 Benign prostatic hyperplasia (BPH), 269–271
 Benzene, **340**, **364**
 Benzodiazepines, 248–249
 Benzoylcegonine, 248
 Bernard-Soulier syndrome, 391
 Beta blockers, **144**
 Bicarbonate, 29, **33**, 35, **36**, 38, 73
 Bicarbonate buffer system, 37
 Bile duct obstruction, 226
 Bile pigments
 excretion, 220–221, **222**
 urine, 81, **81**
 Bile salts
 absorption test, 214
 deficiency, 216
 fecal, 213
 Biliary atresia, 221, **222**
 Biliary tract obstruction, 81
 Bilirubin, 220–221, **222**
 conjugated, 220
 serum, 220–221, 345
 unconjugated, 220
 urine, 81, **81**, 223
 Bilirubinuria, 223
 Biotinidase, 534
 Biphosphonates, **48**
 Bite cells, 351
 Biuret method, serum proteins, 122
 Blackfan-Diamond syndrome, 342
 Bladder cancer, **180**, 279
 Bleeding disorders, 392–397
 Bleeding patient, 386–392
 clinical evaluation, 387–390
 laboratory evaluation, 390–392
 Bleeding time, 391
 Blister cells, 351
 Blood
 CSF, 96–97, **97**
 drug screen, 249
 gamma irradiation, 443
 specimen for cytogenetic studies, 310
 urine, 80
 Blood bank. *See* Transfusion medicine
 Blood-brain barrier, 135–136
 Blood culture, 473–474
 Blood gases, 33–37
 background, 26
 calculated parameters, 35–36
 measured parameters, 34–35
 reference ranges, **36**
 substance abuse screening, 246
 venous, 36, **36**
 Blood loss, anemia due to, 331–332, **331**
 Blood salvage, intraoperative, 444
 Blood smear, 463
 Blood tests
 intestinal malabsorption, 215
 pediatric patient, 528–532, **529–530**
 Blood urea nitrogen (BUN), 62, 247
 B lymphocyte(s), 370–373, **373–374**
 antigen associated with, **371**
 CD antigens, **373–374**
 clonality status, **381**
 in vitro function test, 461
 quantification, **460**, 461
 B lymphocyte defects, 458, **459–460**, 460–461
 Bone, markers of bone turnover, 52–53, **53**
 “Bone burns,” 227, 275–276
 Bone cancer, 276
 Bone disease, 227
 Bone marrow, 337
 in anemia, **342**
 cytogenetic analysis, 307–308, **308–309**
 erythroid hyperplasia, 348
 specimen for cytogenetic studies, 311
 Bone marrow failure, 332
 primary, 340–342, **341**
 Bone marrow suppression, **331**, 338, 364, **364**
Bordetella pertussis, 477, 520
Borrelia, 485
Borrelia burgdorferi, 520
 Boyden chamber, 465
 BPH. *See* Benign prostatic hyperplasia
 Brain abscess, 99–100, **180**
 Brain tumor, 100, **180**, **361**
 Branched-chain DNA signal amplification, 316, **316**
 Breast cancer, 50, **107**, **263**, 268–269, 279, **320**
 Broad beta disease, 147
 Bronchial brushings, 478
 Bronchoalveolar lavage, 478–479
 Broth macrodilution method, antimicrobial susceptibility testing, 488
 Broth microdilution method, antimicrobial susceptibility testing, 488
 Brucellosis, 364, **368–369**, 474, 506
 Budd-Chiari syndrome, 414
 Buffer systems, blood, 35, 37
 Bullous pemphigus, **450**
 BUN. *See* Blood urea nitrogen
 Burns, 28, 80, 362, **466**
- ## C
- C2 complement protein deficiency, **460**
 C3 complement protein, **128**, 130, 453
 deficiency, **460**
 C4 complement protein, **128**, 130, 453
 deficiency, **460**
 C5–9 complement proteins, deficiency, **460**
 Cachexia, **364**
 Caffeine, **68**
 Calcitonin, 45, **46**, **48**
 as tumor marker, **263**, 274
 Calcium, 42, **53**
 bone, 42
 CSF, 102
 dietary, 42
 excretion, 42
 hormonal regulation, **43**
 ionized, 31, **33**, 46–47
 plasma, 46–47
 protein-bound, 46
 tests for calcium metabolism, 43, **43**
 total, 47
 Calcium phosphorus product, blood, 50
 Calcium pump, 42
 Calcium soaps, 50

- Calcofluor white, 486
Calymmatobacterium granulomatis, 481
Campylobacter, 479, 484
 Cancer. *See also specific sites*
 chromosome abnormalities, 307–308, **308–309**
 molecular diagnostics, **320**, 321–323
 proto-oncogenes, 323
 T- and T-cell gene rearrangements, 322
 translocations, 322
 tumor markers. *See* Tumor markers
 tumor suppressors, 323
 Cancer antigens, 266–267
 CA 15–3, **263**, 268
 CA 19–9, 207, **263**, 268
 CA 125, **263**, 267
Candida, 90, 481, 521
 Candidiasis, **459**, 479
 Cannabinoids, 248
 Capacitation, 543
 Capillary draws, 530–531, **531**
 Carbamazepine, **258**
 Carbohydrate malabsorption, 211
 Carbon dioxide, partial pressure
 blood, 33, 35, **36**
 CSF, 102
 Carbonic anhydrase III, 239
 Carbon tetrachloride, **368**
 Carcinoembryonic antigen (CEA), 207, **263**, 269
 peritoneal effusion, 115
 serous effusions, 111
 Carcinoid, 164, 176, 192, **263**, 277
 Carcinoid syndrome, 277
 Carcinomatosis
 abdominal, 115
 meningeal, 101
 peritoneal, 115
 Cardiac trauma, 240
 Cardiomyopathy, 252
 Carnitine palmityltransferase deficiency, 193
 Casts, urine, 85–88, **86**
 Catecholamines
 plasma, 168
 urine, 168
 Cat-eye syndrome, 306
 Cat-scratch disease, 520
 CBC. *See* Complete blood count
 CD antigens, **373–374**
 Celiac sprue, 210, 214, 217
 Cells
 CSF, 98–99
 peritoneal effusion, 114
 serous effusions, 109
 urine, 84–85
 Central nervous system cancer, 362
 Central nervous system disease, **78**
 Centrifugation culture, virus, **494**, 496
 Cephalixin, 83
 Cephalothin, 83
 CEA. *See* Carcinoembryonic antigen
 Cerebral hemorrhage, **94–95**
 Cerebral thrombosis, **94–95**
 Cerebrospinal fluid (CSF), 93–104
 background, 94–96, **94–95**
 collection, 96
 Cerebrospinal fluid (CSF) analysis
 blood, 96–97, **97**
 calcium, 102
 cells, 98–99
 chemistry determinations, 100–103
 chloride, 102
 clotting, 98
 C-reactive protein, 103
 diagnosis of infectious disease, 475
 diagnosis of viral disease, **493**
 electrolytes, pH, and gases, 102
 enzymes, 102
 glucose, 101–102
 glutamine, 103
 in HIV infection, 104
 laboratory assays, 98–99
 microbiologic, 103–104
 protein, 100–101
 visual interpretation, 96–98
 Cerebrospinal fluid (CSF) protein electrophoresis, 101, 135–136
 Cerebrovascular accident, 39
 Cerebrovascular thrombosis, 100
 Ceruloplasmin, **128**, 129, 234
 Cervical mucus, 547
 Cervical secretions, 480
 Cervicitis, 480–481
 CGD. *See* Chronic granulomatous disease
 CH50 total hemolytic complement assay, 453, 465
 Chancroid, 480, 484
 Chédiak-Higashi syndrome, **460**, 463
 Chemotactic ability, neutrophils, 465
 Chest pain, 238
 Chest Pain Evaluation Center, 236
 Chest pain triage, 241–244, **242**
 Chest trauma, 108
 Child. *See* Pediatric patient
Chlamydia, 479, 485–486, 543
Chlamydia trachomatis, 480–481, 520
 Chloramphenicol, **258**, **340**, **364**
 Chloride, 29, **33**
 CSF, 102
 sweat, 208, 535–536
 Chloroform, **247**
 Chlorpropamide, **180**
 Cholangitis, **455**
 Cholecalciferol, 44
 Cholecystitis, 206
 Cholecystokinin-pancreozymin, 203, 209
 Cholelithiasis, **222**
 Cholelithiasis, 206
 Cholestasis, **144**, 216, 221, 227
 Cholesterol, 141
 HDL cholesterol, 140, **142**, 143, 145, 148
 LDL cholesterol, 143–144, 148, **407**
 peritoneal effusion, 115
 pleural fluid, 110
 total, 142–144, **142**, 148
 Choly-¹⁴C-glycine breath test, 213
 Choriocarcinoma, 273
 Chorionic villus sample, cytogenetic studies, 311–312
 Chromatography, drug screen, 250–251
 Chromosome abnormalities, 282–283, 288, **289**
 acquired, 307–308, **308–309**
 constitutional, 304–307, **305**
 infertility and, 544
 postnatal analysis, 307
 prenatal screening, 306
 Chronic granulomatous disease (CGD), 365, **459**, 464
 Churg-Strauss syndrome, **455**
 Chvosteks/Trousseau signs, 48

- Chylomicron(s), 140, **140**
 Chylomicronemia syndrome, 145–146
 Chylous effusion, 106, 108, **108**, 110, **112**, 115
 Chyluria, **72**
 Cigarette smoking, **407**
 Cimetidine, 61, **177**
 Cirrhosis, **72**, **106**, **112**, 114, 116, 129, 224, 226, **226–227**, 233, 268, **368**, **466**, 511
 primary biliary, 232, **450**
 Cisplatin, **48**
 Clarity
 CSF, 97–98
 peritoneal effusion, 113
 serous effusions, **108**
 synovial fluid, 118, **118**
 urine, 71, **72**
 Clearance, renal, 56, **57**, 59
 Clinical laboratory. *See* Laboratory entries
 Clinitest tablets, 79
 Clofibrate, **180**
 Clomipramine, **259**
 Clonal expansion, 380
 Clonality status
 B cells, **381**
 T cells, **382**
Clostridium sepsis, 353
 CLO-test, 199, 484
 Clotting, of CSF, 98
 Clotting factors, 387, 405. *See also specific factors*
 deficiencies, 392–396
 Clue cells, 481
 CMV. *See* Cytomegalovirus
 Coagulation cascade, 386, 451
 Cocaine, 248
 Coccidioidomycosis, 99, 521
 Codeine, 248
 Coefficient of variation, 21
 Cold agglutinins, 432–433
 Donath-Landsteiner test, 433
 thermal amplitude study, 433
 titer, 432
 Collagen vascular disease, 110–111, **353**, **361**, 362, 366, **368**, 399
 Color
 CSF, 97
 peritoneal effusion, 113
 serous effusions, **108**
 synovial fluid, 118, **118**
 urine, 71, **71**
 Colorectal cancer, **263**, 268–269, 279
 Combined hyperlipidemia, **141**, 146–147, 149
 Common variable immunodeficiency disease, 459, 461, **462**
 Compensated polarized light microscopy, synovial fluid, 119–120
 Complement fixation test, histoplasmosis, 507
 Complement system, 402
 complement fractions assay, 453–454
 defects, 458, **460**, 465
 Complete blood count (CBC), 326–329, **329**
 Compliance plan, 7
 Congestive heart failure, 87, **106**, **112**, 114, 227, **407**
 Connective tissue disease, 111
 Contaminants, urine, 91
 Copper, 353
 Copper reduction test, glucosuria, 78–79
 Core laboratory concept, 4
 Coronary angiography, 238
 Coronary artery disease, 149–150
 risk factors, 142, **143**, 144–147
 Coronavirus, **493**
 Corticosteroids, urine, 165
 Corticosteroid therapy, 38, 62, **78**, 157, **466**
 Corticotropes, 173
 Corticotropin. *See* Adrenocorticotropic
 Corticotropin-releasing factor (CRF), 162, **172**
 Cortisol, 162, 164–165, 167–168, **172**, 175
Corynebacterium diphtheriae, 477
 Costs
 cytogenetic studies, 312
 laboratory tests, 10–11
 Coumarin, 397
 monitoring treatment, 417
 C-peptide, 192
 Craniopharyngioma, 175, **177**, 178
 C-reactive protein, 103, **128**, 130
 Creatine kinase
 isoenzyme electrophoresis, 238–239
 isoforms, 239
 Creatinine, 59–62
 Creatinine clearance, 60–62, 204
 CREST syndrome, **449**, 451
 CRF. *See* Corticotropin-releasing factor
 Cri du chat syndrome, 306
 Crigler-Najjar syndrome, 221, **222**
 Critical difference, 21
 Crohn's disease, 210–211, 217
 Crossmatch, 426–427
 electronic, 426–427
 “immediate spin,” 426
 major, 426
 minor, 426
 Crush syndrome, 80
 Cryoglobulinemia, 399, 453
 Cryoprecipitate, 440
 Cryptococcosis, 487, 507
Cryptosporidium, 479, 485–486
 Crystals, urine, 88, **89**
 CSF. *See* Cerebrospinal fluid
 C-telopeptide, **53**
 Cushing's disease, 164, 178
 Cushing's syndrome, 38, **78**, 164–166, 185, **355**
 Cyanotic heart disease, **355**
 Cyclophosphamide, **180**
Cyclospora, 479, 485
 Cyclosporin, **144**
 Cysticercosis, 136
 Cystic fibrosis, 30, 206, 208, **320**, 321
 neonatal screening, 535
 Cystinuria, 299
 Cystitis, viral, **84**
 Cytogenetics, 301–312. *See also* Chromosome abnormalities
 background, 302–303
 costs of studies, 312
 disease states, 304–309
 nomenclature and notation, **303–304**
 specimen information, 309–312
 Cytokeratin 19, CYFRA 21–1, 276
 Cytomegalovirus (CMV), **369**, 485, **493**, **495**
 molecular diagnostics, 522
 Cytomegalovirus (CMV) antibody-negative blood, 444
 Cytomegalovirus (CMV) antigenemia assay, 496–497
 Cytomorphology
 peritoneal effusion, 114
 serous effusions, 109

D

- D antigen, 423, 430
 Darkfield microscopy, 483, 501
 D-dimer assay, 405
 Decision level, 23
 Decision tree, 11–13, **12**
 Deep venous thrombosis, 409, 411, 415–416
 Dehydration, 46, 75, 82, 129, **131**
 Dehydroepiandrosterone (DHEA) sulfate, 162, 166, 168
 Delayed type hypersensitivity reaction, 461, **463**
 Deletion, **304**, 306
 Demethylchlortetracycline, 64
 Demyelinating disorder, 99
 Dendritic cells, **373**
 Dengue, **493**
 Deoxyripyridinoline, **53**
 Deoxyuridine suppression test, 338
 Depression, 165
 DeRitis quotient, 225
 Designer drugs, 249
 Desipramine, **259**
 Desmethylclomipramine, **259**
 Desmethylsertraline, **259**
 Desmethylvenlafaxine, **259**
 Dexamethasone suppression test
 high-dose, 165–166
 low-dose, 164–165
 overnight, 164–165
 DHEA sulfate. *See* Dehydroepiandrosterone sulfate
 Diabetes insipidus, 28, **68**, 74–75, 179
 nephrogenic, 64, 179
 neurogenic, 64, 179
 Diabetes mellitus, 49, 184–187
 anovulation, **547**
 background, 184
 classification, **184**
 gastrin levels, 202
 gestational, **184**, 186, 188, **188**
 hyperlipidemia, **144**
 immunodeficiency, **466**
 laboratory assessment, 186–189
 polyuria, **68**
 proteinuria, 134
 thrombosis, **407**
 Type I (insulin-dependent), **184–185**, 185, 284, **450**
 Type II (non-insulin dependent), 31, **184–185**, 185
 urinalysis, 74, 78–79, **78–79**, 82
 Diabetic acidosis, **361**
 Diabetic ketoacidosis, 52, 186, **186**, 206
 Diabetic nephropathy, 76, 189
 Diabetic neuropathy, 100
 Diagnostic decision-making, laboratory tests in, 9–23
 Diagnostic test, 2, 11
 Diarrhea, 28, 38–39, 479
 Diazo reaction, 220, 223
 DIC. *See* Disseminated intravascular coagulation
 Dicumarol, monitoring treatment, 417
 Diethylether, **247**
 Differential leukocyte count, 109, 358–359, **359**
 DiGeorge syndrome, 49, 306, **459**
 Digital rectal examination, 271, **272**
 Digitoxin, **258**
 Digoxin, **258**
 1,25-Dihydroxyvitamin D, 43–45, **43**, 49, **51**
 24,25-Dihydroxyvitamin D, 45
 Diphtheria, 484
 Direct antiglobulin test. *See* Direct Coombs' test
 Direct Coombs' test, 427–428
 Direct fluorescent antibody test, syphilis, 501
 Direct immunodiffusion test, histoplasmosis, 507
 Disopyramide, **258**
 Disseminated intravascular coagulation (DIC), 352, **353**, 400–406,
 412, 414
 clinical diagnosis, 403
 coagulation tests, 405
 etiologies, **400**
 laboratory diagnosis, 404–406
 molecular markers, 405–406
 morphologic findings, 403–404
 pathophysiology, 400–401, **401**
 Diuretic therapy, 28, 38, **68**, **144**
 Diverticula, 217
 DNA amplification techniques, 315–316, **316**, 518
 limitations, 524–525
 DNA fingerprint, 324
 DNPH test, 297
 Döhle body, 360, **361**
 Donath-Landsteiner test, 433
 Donor blood testing, 433–434
 Dopamine, 157, **172**, 277
 Double-stranded DNA, antibody to, **449**, 452
 Down's syndrome. *See* Trisomy 21
 Doxepin, **259**
 Dram vial culture, 496
 Drug screen, 246
 chromatography, 250–251
 immunoassay, 249–250
 therapeutic drug monitoring, 255–260
 Dubin-Johnson syndrome, 221, **222**
 Duodenal cancer, **180**, **263**
 Duodenal drainage, 483
 Duodenal ulcer, perforated, 206
 Dysbetalipoproteinemia, familial, **141**, 147
 Dyserythropoietic state, **331**
 Dysfibrinogenemia, 392, **407**, 415
 Dysglobulinemia, **144**
- E**
 Ear specimen, 477
 Eastern equine encephalitis, **493**
 EBV. *See* Epstein-Barr virus
 ECG. *See* Electrocardiograph
 Echocardiography, 238
 Eclampsia, **353**, **361**
 Ectopic pregnancy, 283, 285, 290
 Efficiency of test, 13–16
 Effusion, 106
 Electrocardiograph (ECG), 238
 Electroendosmosis, 130
 Electrolytes, 26–33, 247
 anion gap, 30–31, **32**
 background, 26
 bicarbonate, 29
 chloride, 29
 CSF, 102
 intracellular fluid, 27, **27**
 ionized calcium and magnesium, 31
 measurement, 30
 plasma, 27, **27**
 potassium, 28
 reference ranges, **33**

sodium, 27–28

Electron microscopy, 486, 497

Electrophoresis
 apparatus, 124
 CSF proteins, 135–136
 hemoglobin, 350
 lipoproteins, 149
 serum protein, 123–124, **123**, 383, **383**
 urine proteins, 134–135

Elliptocytosis, hereditary, 349

Embryonal cell carcinoma, 276

EMIT. *See* Enzyme multiplied immunoassay technique

Emphysema, 129, 233

Empyema, 110

Encephalitis, 96, 101, **180**, **547**
 herpetic, 486
 viral, **493**, 523–524

Encephalopathy, 103, 252

Endobronchial aspiration, 478

Endocarditis, **368**, 474

Endodermal sinus tumor, 266

Endometrial biopsy, 546

Endometrial cancer, **263**, 267

Endotoxemia, 363

Endotracheal aspiration, 478

End-stage renal disease, 31

Enterococcus, 487

Enterocolitis
 inflammatory, 484
 necrotizing, 484

Enteropathy, protein-losing, 224

Enterovirus, 478, **493**, **495**, 524

Enzymatic tests, for glucosuria, 79

Enzyme-linked immunosorbent assay, HIV antibody, 467

Enzyme multiplied immunoassay technique (EMIT), 249–250

Enzymes
 CSF, 102
 liver function tests, 225–228
 myocardial markers of injury, 238–239
 pancreatic, 203
 peritoneal effusion, 115
 RBC enzymopathies, 351
 serous effusions, 110

Eosinopenia, **358**, 366, **366**

Eosinophil(s), 365–366
 CD antigens, **374**
 CSF, 99
 differential leukocyte count, **359**
 kinetics, 365
 peritoneal effusion, 114

Eosinophilia, **358**, 365–366, **366**

Epinephrine therapy, **366**

Epithelial cell(s), urine, 85

Epithelial cell casts, urine, **86**, 87

Epstein-Barr virus (EBV), **320**, 522

Ergocalciferol, 44

Error
 analytical, 20–21
 postanalytical, 21
 preanalytical, 20, **22–23**
 random, 20–21
 systematic, 20–21

Erythrocyte(s)
 CSF, 98
 urine, 80, 84

Erythrocyte casts, urine, 86–87, **86**

Erythrocyte count, **329**

Erythrocyte disorders, 325–355
 anemia. *See* Anemia
 background, 326
 complete blood count, 326–329, **329**
 normal RBC production and destruction, 329–331
 polycythemia. *See* Polycythemia
 red cell indices, 326–329, **329**

Erythropoiesis
 increased, 348
 ineffective. *See* Ineffective erythropoiesis

Erythropoietin, 343, **355**

Escherichia coli, 479, 506

Esophageal rupture, 110

Estradiol, **172**

Estril, in pregnancy, 282, **283**, 284–285

Estrogen, **177**

Estrogen therapy, **144**, **407**, 412

E-test, 488

Ethanol, **247**
 blood levels, 251–252

Ethanol gelation test, 402

Ethosuximide, **258**

Ethylene glycol, 38, **247**

Ewing's sarcoma, **320**

Exocrine pancreas function tests
 amylase level, 203–204
 background, 203
 indirect tests, 205–206
 lipase level, 204–205
 Lundl test, 205
 secretin cholecystokinin test, 205

Exocrine pancreatic disease, 206–208

Extractable nuclear antigens, antibody to, 452

Exudate, 106, 108–109, **108**, 482

F

Factor V
 deficiency, 392
 Factor V Leiden, 409–411

Factor VII, 387
 deficiency, 392

Factor VIII, 387
 deficiency, 392–393, 395

Factor VIII concentrate, 393, 441
 porcine, 442

Factor VIII inhibitor, 399

Factor IX, 387
 deficiency, 392–394

Factor IX inhibitor, 399

Factor X, 387
 deficiency, 392

Factor XI deficiency, 392

Factor XII deficiency, 392, **407**

Factor XIII deficiency, 392

Fallopian tubes, blocked, 547

False-negative result, 15

False-positive result, 15

FANA test. *See* Immunofluorescent antinuclear antibody test

Fanconi's anemia, 78, **340**

Fat
 droplets in urine, 88
 fecal, 211–212

Fatty casts, urine, **86**, 88

Fatty liver, **227**

FDP. *See* Fibrin(ogen) degradation products

- Fecal culture, 479
 Fecal fat, 211–212
¹⁴C-triolein breath test, 212
 microscopic examination, 211
 quantitative stool fat determination, 212
 Feces, proteolytic activity, 206
 Female infertility, 544–547, **545**
 FEP. *See* Free erythrocyte protoporphyrin
 Ferritin, 333, **336**, 343
 Fertility. *See* Infertility
 Fetal lung maturity, 290–292
 Fetal-maternal hemorrhage, 430
 Fetal-placental function, 284–285
 Fibrin, 386, 399, 402
 Fibrinogen, **128**, 130, 387, 400
 Fibrin(ogen) degradation products (FDP), 400–402, 405
 Fibrinolytic state, 391
 Fibrinolytic system, 397–399
 Fibrinopeptide A, 400, 406
 Fibrinopeptide B, 400
 Fibrin split products, 400
 Fibrosarcoma, **191**, 192
 FISH. *See* Fluorescence in situ hybridization
 Flame photometry, 30
 Flecainide, **258**
 Flow cytometry
 immunophenotyping hematopoietic cell neoplasms, 380–381
 immunophenotyping lymphocytes, 371–374
 polymerase chain reaction with, 317
 Fluorescein dialurate test, 205
 Fluorescence in situ hybridization (FISH), 302–303, 317
 Fluorescence polarization immunoassay (FPIA), 249–250
 Fluorescent treponemal antibody absorption test (FTA-Abs), 503
 Fluorochrome stain, 485
 Fluoxetine, **259**
 Folate
 deficiency, **327**, 336–338, **337**
 RBC, 337, **337**
 serum, 337, **337**
 Folicle-stimulating hormone (FSH), 172–175, **172**, 178, 546, **546**
 in male, **540**, 541–542
 Forensic identity testing, 324
 Forensic toxicology, 246
 FPIA. *See* Fluorescence polarization immunoassay
 Fragile X syndrome, **305**, **320**, 321
 Free erythrocyte protoporphyrin (FEP), 333, **336**
 Fresh-frozen plasma, 439
 Friedewald equation, **227**
 Froin's syndrome, 98, 100
 Fructose, in ejaculate, 539
 Fructose intolerance, 190, **191**, 193
 Fructosuria, 79
 FSH. *See* Folicle-stimulating hormone
 fT₃. *See* Triiodothyronine, free
 fT₄. *See* Thyroxine, free
 FTA-Abs. *See* Fluorescent treponemal antibody absorption test
 Fungal infections
 immunologic tests, 507
 molecular diagnostics, 521
 Fungemia, 473–474
 Fungi
 CSF, 103–104
 urine, 90
 Furosemide, 64
- ## G
- Gabapentin, **258**
 Galactosemia, 79, 190, **191**, 193, 534
 Gamma-glutamyltransferase (GGT), serum, 226–228, 276
 Gamma irradiation, blood, 443
Gardnerella vaginalis, 481
 Gas chromatography (GC), drug screen, 250–251
 Gas chromatography/mass spectrometry (GC/MS), drug screen, 250–251
 Gas gangrene, 484
 Gastric acid output, 200–201
 Gastric antral biopsy, *Helicobacter pylori*, 484
 Gastric cancer, 200, 202, **263**, **361**, 362
 Gastric mucosa, *Helicobacter pylori*, 198–199
 Gastric outlet obstruction, 202
 Gastric secretion, laboratory tests, 200–202
 Gastrin
 serum, 201–202
 as tumor marker, **263**, 274–275
 Gastrinoma, 201–202, **263**, 274–275
 Gastritis, 196–199, 201–202
 Gastroenteritis, 486
 eosinophilic, 214
 Gastrointestinal cancer, 268
 Gastrointestinal disorder, hypokalemia, 28
 Gastrointestinal tract
 background, 196
 gastric secretion, 200–202
 tests of *Helicobacter pylori*, 196–199
 Gastrointestinal tract perforation, 113, 115
 Gastrointestinal tract specimen
 diagnosis of infectious disease, 479
 diagnosis of viral disease, **493**
 Gaucher disease, **368**
 GC. *See* Gas chromatography
 Genetic disease testing, 319–320, **320**
 direct mutation analysis, **320**, 321
 linkage analysis (indirect analysis), 319–321, **320**
 Genetics, clinical, 295
 GENE-TRAK, 316
 Genital tract infection, 543
 Genital ulcer, 480–481
 Genitourinary tract specimen, diagnosis of infectious disease, 480–481
 Gentamicin, **258**
 Germ cell tumor, 233, **263**, 266, 273–274, 284
 Gestational diabetes, **184**, 186, 188, **188**
 Gestational trophoblastic disease, 274
 GFR. *See* Glomerular filtration rate
 GGT. *See* Gamma-glutamyltransferase
 GH. *See* Growth hormone
 GHRH. *See* Growth hormone-releasing hormone
 Giardiasis, 486
 Giemsa stain, 485
 Gigantism, 176
 Gilbert's syndrome, 221, **222**
 Glanzmann's thrombasthenia, 391
 Glioma, **547**
 Glitter cells, 85
 α_1 -Globulins, 129
 α_2 -Globulins, 129
 β_1 -Globulins, 130
 β_2 -Globulins, 130
 γ -Globulins, 130–131
 Glomerular filtration rate (GFR), 58–62
 Glomerulonephritis, 76, 134
 acute, 84, 87

membranoproliferative, 132
 membranous, 132
 Pauci immune, **455**
 poststreptococcal, **84**, 505–506
 Glomerulosclerosis, focal segmental, 132
 Glucocorticoids, 162
 Glucocorticoid therapy, 185, 361, **361**, **366–368**, **370**
 Glucose
 CSF, 101–102
 fasting plasma glucose value, 187
 peritoneal effusion, 114–115
 plasma, 101, 187, 190
 serous effusions, 110
 2-hour plasma glucose value, 187
 urine, 78–79, **78–79**
 Glucose intolerance, **184**
 Glucose oxidase, 79
 Glucose-6-phosphate dehydrogenase deficiency, 351, **352**, 353, 464
 Glucose tolerance test, 187–188, 216
 Glucosuria, 69, 78–79, **78–79**
 Glutamine, CSF, 103
 Glutaric acidemia, **72**
 Glycated hemoglobin assay, 189
 Glycemic control, monitoring, 189
 Glycerol, **247**
 Glycogen storage disease, **78**, **191**, 193, 296
 Glycosaminoglycan storage disease, 295
 Gn-RH. *See* Gonadotropin-releasing hormone
 Goiter, toxic nodular, 157
 Gonadal dysgenesis, **547**
 Gonadotropes, 173
 Gonadotropin(s), 172–174, **172**
 deficiency, 174
 Gonadotropin-releasing hormone (Gn-RH), 172, **172**
 deficiency, 174
 Gonadotropin-secreting tumor, 178
 Gonorrhea, 480, 487
 Goodpasture's syndrome, **455**
 Gout, **117**, 119, **361**
 Gram's stain, 484
 Granular casts, urine, **86**, 87
 Granulocyte(s), CD antigens, **373–374**
 Granulocyte antigen/antibody tests, 435
 Granulocyte storage pool defects, 391
 Granulocyte transfusion, 440
 Granulocytopenia, **358**
 Granulocytosis, **358**
 Granuloma, 174
 Granuloma inguinale, 481, 485
 Granulomatous disease, **51**, **342**
 Graves' disease, **450**
 "Group, screen, hold." 425
 Growth hormone (GH), 172–173, **172**
 deficiency, 174–175
 excess, 176
 Growth hormone-releasing hormone (GHRH), 172
 Guillain-Barré syndrome, 100–101, 136, **180**

H

Haemophilus, 487
Haemophilus ducreyi, 480
Haemophilus influenzae, 477, 487, 506
 Haptoglobin, **128**, 129, 347, **347**
 HBsAg. *See* Hepatitis B envelope antigen
 HBsAb. *See* Hepatitis B surface antibody
 HBsAg. *See* Hepatitis B surface antigen
 hCG. *See* Human chorionic gonadotropin
 HDL, 140–141, **141**
 HDL cholesterol, 140, **142**, 143, 148
 low levels, 145
 Head and neck cancer, 51
 Head trauma, **180**
 Heart disease, **353**
 Heart failure, 27
 Heat denaturation test, unstable hemoglobin, 350
 Heavy-metal intoxication, 338, **364**
 Heel stick, 530–531, **531**
 Heinz body, 350–351
Helicobacter pylori, 196–199
 gastric antral biopsy, 484
 invasive tests, 198–199
 noninvasive tests, 196–199
 rapid urease test, 199
 serologic tests, 196–197
 testing gastric mucosa, 198–199
 urea breath test, 197–198
 Helper T cells, 371, **371**
 Hemagglutination test for syphilis, 503
 Hemangioblastoma, cerebellar, 355, **355**
 Hemangioma, **117**
 Hematocrit, 326, **329**, 532
 Hematoma. *See specific sites*
 Hematopoietic tumor, **361**
 Hematuria, **72**, 80, 84, 87
 gross, causes of, **84**
 Heme catabolites, 345
 Hemizona assay, 543
 Hemochromatosis, 49, 185, **320**
 Hemodialysis, 47, 363
 Hemodilution, 444
 Hemoglobin, 326, **329**
 buffering capacity, 37
 electrophoresis, 350
 fetal, 430
 plasma, 80
 unstable, 349–350
 variants, 127
 Hemoglobin A₂, 334, **336**
 Hemoglobin C, 127, 349–350
 Hemoglobin casts, 86
 Hemoglobinemia, 80, 347, **347**, 353
 Hemoglobinization, 327–328, **329**
 Hemoglobinopathy, **327**
 structurally abnormal hemoglobins, 349–350
 thalassemia syndromes, 350–351
 Hemoglobin S, 349–350
 Hemoglobinuria, 80, 347, **347**, 353
 Hemolysis, 28, 221, **222**, **327**, **361**
 Hemolytic anemia, 81, **331**, 344–354, 367, **368**, **450**
 acquired, **344**, 351–354
 autoimmune, 345, 349, 352, **352**
 classification, **344**
 diagnostic scheme, **346**
 due to drugs and chemicals, 353
 extrinsic, 344
 hereditary, **344**, 348–351
 infectious disease and, 353
 intravascular, 331
 with intravascular hemolysis, 352, **352**
 intrinsic, 344
 microangiopathic, **344**, 345, 352–353, **352–353**
 plasma lipid abnormalities and, 353–354

- tests of compensatory increase in erythropoiesis, 348
 tests to identify increased RBC destruction, 345–346, **346**
 warm autoimmune, 431–432
- Hemolytic disease of the newborn, 429
- Hemolytic uremic syndrome, **353**
- Hemopexin, **128**, 130
- Hemophilia, **117**, 399
- Hemophilia A. *See* Factor VIII, deficiency
- Hemophilia B. *See* Factor IX, deficiency
- Hemorrhage, **361**. *See also* Bleeding patient; *specific types and sites of hemorrhage*
 spontaneous, 386
- Hemorrhagic disease of the newborn, 397
- Hemorrhagic fevers, **493**
- Hemosiderin, 333
- Hemosiderinuria, 347, **347**, 353
- Hemostasis. *See also* Bleeding patient; Thrombosis
 background, 386
 primary, 386
 regulation, **455**
 secondary, 386
- Henderson-Hasselbalch equation, 33–35, 37
- Heparin cofactor II, **407**, 414
 congenital deficiency, 415
- Heparin therapy, monitoring treatment, 417
- Hepatic disease. *See* Liver disease
- Hepatitis, **223**, **369**, **455**
 acute, **510**
 algorithm for diagnosis, **513**
 cholestatic, **227**
 chronic, **226**, 233, 268, **510**, **511**
 algorithm for diagnosis, **514**
 chronic active, 232, **450**
 chronic autoimmune, 231
 drug-induced, **226**
 infectious, 206
 viral, 221, **222**, 224, **226**, 227–231, 486
 acute, 231
 algorithm for diagnosis, **513–514**
 chronic, 231
 immunologic tests, 509–514
 serum antigens and antibodies, **512**
- Hepatitis A virus, **340**
 antibodies against, 231, 509, **510**
 immunologic tests, 509, **510**, **512**
- Hepatitis B core antigen, 229, 510
 antibody to, 230, 434, 511
- Hepatitis B DNA, 228–229
- Hepatitis B DNA polymerase, 511
- Hepatitis B envelope antigen (HB_eAg), 228–229, 510, **510**
 antibody to, 229, 511
- Hepatitis B surface antibody (HBsAb), 229
- Hepatitis B surface antigen (HBsAg), 228, 434, 510, **510**
 antibody to, 510
- Hepatitis B virus
 immunologic tests, 509–511, **510**, **512**
 molecular diagnostics, 523
- Hepatitis B virus RNA, 230–231, 510
- Hepatitis C virus, 323, 434
 immunologic tests, **510**, **511**, **512**
 molecular diagnostics, 523
- Hepatitis C virus antibody, 230–231
- Hepatitis D virus, immunologic tests, 511–512, **512**
- Hepatitis E virus, immunologic tests, 512
- Hepatocellular carcinoma, 192, 228, 233, **263**, 266, **355**, 511
- Hepatocellular damage, 227
- Hepatoma, **191**
- Hepatotoxicity, 252
- Heroin, 248
- Herpes simplex virus, **320**, 478, 481, **493**, **495**, 523–524
- Herpes virus, 485
- Heterophil antibody, 158
- 5-HIAA. *See* 5-Hydroxyindoleacetic acid
- High-molecular-weight kininogen deficiency, 392
- High-performance liquid chromatography, bilirubin fractions, 220
- High-pressure liquid chromatography (HPLC), drug screen, 250–251
- Histiocytosis, **466**
- Histocompatibility typing, 436
- Histones, antibodies to, **449**
- Histopathology, viral infections, 497
- Histoplasmosis, 487, 507, 521
- HIV disease, 101, 136, **320**, **371**, **466**
 algorithm for diagnosis, **468**
 antiphospholipid-thrombosis syndrome, 416
 bacteremia, 474
 CSF evaluation, 104
 diagnosis, 466–469
 hemostasis, **455**
 HIV antibody tests, 467–468
 lymphocytopenia, 370, **370**
 molecular diagnostics, 521–522
 neonates, 521–522
 pediatric patient, 468
 predicting progression, 469–470, **469**
 testing of donor blood, 434
 T lymphocytes, **372**
 viral load, 323, 521
- HLA typing, 436
- Hodgkin's disease, **370**, 378–380, **380**, **466**
- Homeostasis, 26
- Homocystinemia, **407**
- Homocystinuria, 297, 534
- Homovanillic acid (HVA), **263**, 277–278
- HPLC. *See* High-pressure liquid chromatography
- hTG. *See* Human thyroglobulin
- Human chorionic gonadotropin (hCG)
 in pregnancy, 273, 282, **283**, 286–288, 290
 serum, 286–287
 as tumor marker, **263**, 273–274
 urine, 286
- Human papillomavirus, 522–523
- Human thyroglobulin (hTG), **263**, 272–273
- Human T-lymphotropic virus, 434
- Humoral hypercalcemia of malignancy, 265
- Hungry bone syndrome, 50
- Huntington's disease, **320**, 321
- HVA. *See* Homovanillic acid
- Hyaline casts, urine, 86, **86**
- Hyaline membrane disease, 286, 290
- Hyaline microthrombi, 404
- Hyaluronic acid, 116, 119
- Hydatidiform mole, 273
- Hydrogen breath test, 213
- 5-Hydroxyindoleacetic acid (5-HIAA), **263**, 276–277
- 11 α -Hydroxylase deficiency, 168
- 21-Hydroxylase deficiency, 167
- Hydroxylysine, **53**
- Hydroxyproline, **53**
- 25-Hydroxyvitamin D, 44, 48–49
- Hyperalbuminemia, 129
- Hyperaldosteronism, 28, 38, 166–167
- Hyperalimentation, 52
- Hyperbetalipoproteinemia, 149
- Hyperbilirubinemia, 220–221, **222**, 345, **347**

- conjugated, 221, **222**
 - unconjugated, 221, **222**
 - Hypercalcemia, **43**, 47, 50–52, **51**, 64, 264–265
 - Hypercalciuria, **84**
 - Hyperchloremia, 29
 - Hyperchlorhydria, 275
 - Hypercholesterolemia, 140, 142–144, **142–144**
 - combined hyperlipidemia, 146–147, 149
 - familial, **141**, 143–144
 - laboratory assessment, 148–150
 - polygenic, 144
 - secondary, **144**
 - Hypercoagulable states, 406–418
 - Hyper eosinophilic syndrome, **366**
 - Hypergammaglobulinemia, 428
 - Hypergastrinemia, 202, 275
 - Hyperglycemia, 78, 186, 189
 - Hyper-IgM syndrome, **459**, 461, **462**
 - Hyperkalemia, 28
 - Hyperlipidemia. *See also* Hypercholesterolemia; Hypertriglyceridemia
 - combined, 142, 146–147
 - laboratory assessment, 148–150
 - secondary, **144**, 150
 - Hyperlipoproteinemia, 142, 146, 148–150
 - Hypernatremia, 27–28
 - Hyperosmolar hyperglycemic nonketotic coma, 186
 - Hyperparathyroidism, 45, 47, **51**, **68**, 265
 - primary, 50–52
 - secondary, 50–51
 - Hyperphosphatemia, 49–50, 52
 - Hyperprolactinemia, 177, **177**, 546
 - Hypersensitivity state, **361**
 - Hypersplenism, **344**, 364, **364**
 - Hypertension, **353**, **407**
 - with hypokalemia, 167
 - Hyperthyroidism, 51, **78**, 153–159, **155**, **367**, 369, **547**
 - autoimmune, 157
 - secondary, **158**
 - Hypertriglyceridemia, 142, 145–146, **145**, 206–207, **407**
 - combined hyperlipidemia, 146–147, 149
 - familial, **141**, 146
 - laboratory assessment, 148–150
 - secondary, **144**
 - Hyperviscosity syndrome, **407**
 - Hypoalbuminemia, **48**, 129, 224
 - Hypocalcemia, 45–50, **48**
 - Hypochloremia, 29
 - Hypocoagulable state, 397
 - Hypofibrinogenemia, 392
 - Hypogammaglobulinemia, **131**, 132–133, **383**
 - transient, of infancy, **459**
 - Hypoglycemia, 101, 190–193
 - alcohol-induced fasting, **191**
 - background, 184
 - in childhood, 192–193
 - fictitious, 192
 - fasting, 190–191, **191**
 - insulin-induced, 163–164, 175
 - reactive, 190, **191**
 - Hypoglycorrhachia, 101–102
 - Hypogonadism, 49, **542**
 - Hypokalemia, 28, 73
 - Hypokalemic alkalosis, 166–167
 - Hypomagnesemia, 48, 50
 - Hyponatremia, 27–28, 180
 - Hypoparathyroidism, 48–49, **48**, 52, **450**
 - Hypophosphatemia, 45, 49, 52
 - Hypopituitarism, 174–175, **191**
 - Hypoplastic anemia, 340–342
 - Hypoproteinemia, 46
 - Hyposthenuria, 74
 - Hypothalamic hamartoma, 176
 - Hypothalamus, 162
 - regulation of pituitary, 172, **172**
 - Hypothyroidism, **144**, 153–159, **155**, **177**, 239, **327**, 338, 367, **367**, 546, **547**
 - congenital, 534
 - secondary, **158**, 174
 - Hysterosalpingography, 547
- I**
- ICON, 287
 - Ictotest tablets, 81
 - Identity testing, **320**, 324
 - IDL, 141
 - IEP. *See* Immunoelectrophoresis
 - IFE. *See* Immunofixation electrophoresis
 - IGF. *See* Insulin-like growth factors
 - Ileal dysfunction, 213
 - Ileal function test, 215
 - Imipramine, **259**
 - Immune complex disease, 134
 - Immune microscopy, 486
 - Immunoassay, drug screen, 249–250
 - Immunoblot assay, HIV antibody, 467
 - Immunodeficiency disease, 371, 457–470
 - acquired, 466–470, **466**
 - background, 458
 - B lymphocyte defects, 458, **459–460**, 460–461
 - complement system defects, 458, **460**, 465
 - congenital, 370, **370**
 - HIV disease. *See* HIV disease
 - mixed B and T lymphocyte defects, 458, **459**
 - phagocytic cell defects, 458, **459–460**, 463–465, **464**
 - primary, 458–465, **459**
 - T lymphocyte defects, 458, **459**, 461–463, **462**
 - Immunodiagnosis, viral disease, 496
 - Immunoelectrophoresis (IEP), serum proteins, 126, 383
 - Immunofixation electrophoresis (IFE)
 - serum proteins, 124–126, **125**, 383
 - urine proteins, 126
 - Immunofluorescent antinuclear antibody (FANA) test, 448–450
 - Immunofluorescent assay, HIV antibody, 467
 - Immunoglobulin, 130
 - IgA, **128**, 130
 - IgA nephropathy, **84**
 - IgD, 130
 - IgE, 130
 - IgG, **128**, 130, 135
 - CSF, 101
 - IgG subclass deficiency, **459**, 461, **462**
 - IgM, **128**, 130
 - quantitation, **460**, 461
 - Immunoglobulin concentrate, intravenous, 443
 - Immunologic tests
 - background, 500
 - bacterial infections, 500–506
 - fungal infections, 507
 - infectious disease, 499–514
 - parasitic infections, 508
 - serous effusions, 111
 - viral diseases, 509–514

Immunophenotyping
 hematopoietic cell neoplasms, 380–381
 lymphocytes, 370–373, **373–374**

Immunoradiometric assay, parathyroid hormone-related protein, 265

Immunoreactive trypsin (IRT) test, cystic fibrosis, 535–536

Imprecision in laboratory test, 21

Inborn errors of metabolism. *See* Inherited metabolic disease

India ink preparation, 483

Indirect Coombs' test, 424

Inductively coupled plasma emission spectroscopy, metal analysis, 252

Ineffective erythropoiesis
 myelodysplastic syndromes, 338, **339**
 nutritional deficiencies, 332–338

Infection
 leukocyte count, **363**
 lymphocytosis, 369
 neutropenia, 364
 neutrophilia, 362

Infectious disease, 471–488. *See also specific pathogens*
 antimicrobial susceptibility testing, 487–488
 background, 472
 hemolytic anemia in, 353
 immunologic tests, 499–514
 microscopic examination, 482–487
 molecular diagnostics, **320**, 323, 517–525
 specific specimens and associated diseases, 473–482
 specimen selection and collection, 472–473
 specimen transport, 473
 viral. *See* Viral infections

Infectious mononucleosis, **227**, 364, 369, **369**

Infertility
 background, 538
 causes and incidence, **538**
 evaluation of infertile female, 544–547, **545**
 evaluation of infertile male, 539–544, **541**
 idiopathic infertility in men, 543

Inflammation, serum proteins, 131–132, **131**

Inflammatory bowel disease, 454, **455**

Inflammatory response, neutrophilia, 362

Influenza virus, 478, **493**, **495**

Inherited metabolic disease, 293–299. *See also* Genetic disease testing
 background, 294
 clinical and laboratory examination, 295–297
 clinical genetics, 295
 diseases of large molecules, 295–296, **296**
 diseases of small molecules, 297, **298–299**
 metabolic screening, 297–299
 pathways involved in, **294**

Inorganic phosphate, 42

In situ hybridization, 317, 518

Insulin. *See also* Diabetes mellitus
 plasma, 28

Insulin-induced hypoglycemia test, 163–164, 175

Insulin-like growth factors (IGF), **172**, 173, 176

Insulinoma, 191–192, **191**

Insulin resistance, 185–186

Intestinal ischemia, 206

Intestinal malabsorption, **131**, 397
 background, 209–210
 bacterial overgrowth tests, 213–214
 bile salt absorption, 214
 bile salt deficiency, 216
 blood tests, 215
 evaluation of absorptive abnormalities, 210–211
 fecal fat, 211–212
 lactase deficiency, 215–216
 peroral mucosal biopsy, 214

radiologic tests, 217
 terminal ileal function, 215
 D-xylose absorption test, 212–213

Intestinal obstruction, 206

Intestinal strangulation, 115

Intracerebral hemorrhage, 100

Intravascular hemolysis, 86, 352, **352**

Intravenous immunoglobulin concentrate, 443

Intrinsic factor, 215, 337

Inulin, 59

Invasive mole, 273

Inversion, **304**

Iodine stain, 485

Ion-selective electrode (ISE), 30–31

Iron, **247**
 ferrokinetic studies in hemolytic anemia, 348
 serum, 333, 343

Iron deficiency anemia, **327**, **331**, 332–335, **334**

Iron stores, 333, 343

IRT test. *See* Immunoreactive trypsin test

ISE. *See* Ion-selective electrode

Islet cell carcinoma, 276

Islet cell tumor, **78**, 164, 176

Isochromosome, **304**

Isoelectric focusing, serum proteins, 126–127

Isohemagglutinin assay, ABO blood group, 460, **460**

Isoniazid, **247**

Isopropanol, **247**

Isopropanol precipitation test, unstable hemoglobin, 350

Isospora, 479, 485

Isosthenuria, 74

Isotretinoin, **144**

Isovaleric acidemia, **72**

J

Jaundice, 220–221
 cholestatic, 226, **226**
 obstructive, 224

Jejunum culture, 214

Job's syndrome, 461

K

Kallmann's syndrome, 174

Karyotype, 302

Kasabach-Merritt syndrome, **353**

Ketoacidosis, 39
 diabetic, 52, 186, **186**, 206

Ketoconazole, 163

Ketone bodies, 186

Ketonuria, **72**, 82

17-Ketosteroids, urine, 165

Kidney disease. *See* Renal disease

Kinin system, 402

Kinyoun carbolfuchsin stain, 485

Kjeldahl method, serum proteins, 122

Klinefelter's syndrome, 305, **305**, 541, **541**

Kostmann syndrome, 364

L

Laboratory
 compliance plans, 7

- organization and structure, 3–4
- Laboratory director, 3
- Laboratory-physician interaction, 1–7
- Laboratory test
 - appropriate use, 5–6
 - clinical usefulness, 5
 - costs, 10–11
 - diagnostic, 2, 11
 - in diagnostic decision making, 5, 9–23
 - efficiency, 13–16
 - errors in. *See* Error
 - monitoring treatment, 3, 11
 - overuse, 6, 10
 - predictive value, 5, 13–16
 - reference intervals, 18–20
 - reporting results, 3–4
 - research, 11
 - role of laboratory testing, 2–3
 - screening, 2, 11
 - selection, 2
 - sensitivity, 5, 13–16, **16**
 - specificity, 5, 13–16, **16**
 - underuse, 6, 10
- Laboratory test ordering, 3
 - compliance plans, 7
 - priorities, 5
 - routine order, 5
 - STAT tests, 5
- Lactase deficiency, 215–216
- Lactate, peritoneal effusion, 115
- Lactate dehydrogenase (LD)
 - isoenzyme electrophoresis, 238–239
 - peritoneal effusion, 114
 - serous effusions, 109
 - serum, in hemolytic disorders, 347, **347**
- Lactic acidosis, 82
- Lactose hydrogen breath test, 216
- Lactose tolerance test, 216
- Lactosuria, 79
- Lactotropes, 173
- LAD. *See* Leukocyte adhesion defect
- Lamotrigine, **258**
- Langer-Giedion syndrome, 306
- Latex agglutination test, cryptococcosis, 507
- LAT syndrome. *See* Lupus anticoagulant-thrombosis syndrome
- LD. *See* Lactate dehydrogenase
- LDL, 140–141, **140**
- LDL cholesterol, 143–144, 148, **407**
- Lead, 333, 353
- Leber's hereditary optic neuropathy (LHON), 295
- Left ventricular failure, **407**
- Legionella*, 479, 486–487
- Leishmaniasis, **368**
- Leukemia, 96, **107**, **342**, **358**, 375–384, **466**
 - acute, 308, **375**, 376
 - acute lymphocytic, **308**, **320**, 376, **377**, 412
 - acute myeloid, **308–309**, 376, **376**
 - acute promyelocytic, **320**
 - adult T-cell, 265
 - chromosome abnormalities, 307–308, **308–309**
 - chronic, **375**, 376–378
 - chronic granulocytic, 367
 - chronic lymphocytic, 133, 377–378
 - chronic myeloid, 308, **320**, **377–378**, 378
 - classification, **375**
 - diagnosis, **375**
 - diagnostic utility of CD antigens, **373–374**
 - granulocytic, 99
 - hairy cell, **368**
 - lymphocytic, 99, 369, **369**
 - lymphoid, 264, **375**
 - myeloid, **375**
- Leukemogenesis, 380
- Leukemoid reaction, **361**, 362–363
- Leukocyte(s). *See also* Basophil(s); Eosinophil(s); Lymphocyte(s); Monocytes; Neutrophil(s)
 - CSF, 98–99
 - urine, 83–85
- Leukocyte adhesion defect (LAD), **459**
 - type I, 464–465
 - type II, 465
- Leukocyte casts, urine, **86**, 87
- Leukocyte counts, 463, **464**
- Leukocyte disorders, 357–384
 - background, 358–359
 - differential leukocyte count, 358–359, **359**
 - neoplastic, 374–384, **375**
 - quantitative changes in blood leukocytes, **358**
- Leukocyte esterase, urine, 82–83
- Leukocyte-reduced blood, 443
- Leukocytosis, **358**
- Leukoerythroblastic reaction, 342
- Leukostasis syndrome, **407**
- Levodopa, 82
- LH. *See* Luteinizing hormone
- LHON. *See* Leber's hereditary optic neuropathy
- Licorice, 167
- Liddle's syndrome, 167
- Lidocaine, **258**
- Ligase chain reaction, 316, **316**
- Lineage fidelity, 380
- Linkage analysis, 319–321, **320**
- Lipase, serum, 204–205
- Lipids, 139–150
 - background, 140–142
 - peritoneal effusion, 115
 - plasma abnormalities and hemolytic anemia, 353–354
 - serous effusions, 110
- Lipiduria, 88
- Lipoprotein(s), 139–150
 - background, 140–142
 - classes, 140, **140**
 - electrophoresis, 149
 - α_1 -Lipoprotein, **128**, 129
 - β -Lipoprotein, 130
 - Lipoprotein(a), 150, **407**
- Lipoprotein lipase (LPL), 140–141, 149
 - deficiency, **141**, 146
- Liquid capillary electrophoresis, 124
- Lissencephaly, 306
- Lithium, **51**, 64, **259**
- Liver cancer, 226, **263**, **361**
- Liver disease, **78**, **177**, 216, 257, 276, 284, 338, 414
 - alcoholic, 225, **226**, 233
 - bleeding disorders, 397
 - serum proteins, **131**, 132
- Liver function tests, 219–234
 - α_1 -antitrypsin, 233
 - alpha-fetoprotein, 233
 - based on bile pigment excretion, 220–221, **222**
 - ceruloplasmin, 234
 - enzyme tests to establish hepatocellular damage, 225–228
 - hepatic synthetic function, 223–224
 - serologic studies, 228–232

urine bilirubin, 223
 LLD. *See* Lower limit of detection
 Lower limit of detection (LLD), 19
 LPL. *See* Lipoprotein lipase
 Lumbar puncture, 96, 100, 475
 traumatic, **94–95**, **97**, 98, 100
 Lundl test, 205
 Lung abscess, **180**
 Lung cancer, 51, **107**, 164, 176, **263**, 268, 276, **361**, 362
 Lungs, fetal lung maturity, 290–292
 Lupus, **449**
 neonatal, 452
 Lupus anticoagulant, 399, **469**
 Lupus anticoagulant-thrombosis (LAT) syndrome, 416
 Luteinizing hormone (LH), 172–175, **172**, 178, 546, **546**
 in male, **540**, 541–542
 Lyme disease, 119, 136, 520
 Lymphatic duct obstruction, 210
 Lymphoblast, 376
 Lymphocyte(s), 369–384
 CD antigens, **373–374**
 differential leukocyte count, **359**
 immunophenotyping, 370–373, **373–374**
 peritoneal effusion, 114
 Lymphocyte count, total, 461
 Lymphocytopenia, **358**, 370, **370**
 Lymphocytosis, **358**, 369, **369**
 Lymphogranuloma venereum, 481
 Lymphoma, 106–107b, 112b, 114, 130, 180b, 210, 342b, 352, 369,
 369b, 396, 466b. *See also* Hodgkin's disease; Non-Hodgkin lymphoma
 Burkitt's, 101
 diagnostic utility of CD antigens, **373–374**
 EBV-associated, 522
 Lymphoproliferative disorder, 109, 124, 130, 382
 X-linked, **459**
 Lysosomal storage disorders, 295

M

Macroamylasemia, 208
 α_2 -Macroglobulin, **128**, 129, 398
 Macroglubinemia, 398
 Macro-ovalocytes, 336
 Magnesium, 48
 deficiency, **48**
 ionized, 31, **33**
 Malabsorption. *See* Intestinal malabsorption
 Malaria, 353, 364, **368**
 Male infertility, 539–544, **541**
 Malnutrition, **131**
 Mannitol, **247**
 Maple syrup urine disease, **72**, 534
 Maprotiline, **259**
 “March” myoglobinuria, 80
 Mass balance principle, 56, **57**
 Mass spectrometry
 drug screen, 250–251
 metal analysis, 252
 MCH. *See* Mean cell hemoglobin
 MCHC. *See* Mean corpuscular hemoglobin concentration
 MCTD. *See* Mixed connective tissue disease
 MCV. *See* Mean cell volume
 Mean cell hemoglobin (MCH), 328, **329**
 Mean cell volume (MCV), 326–327, **329**, 338
 Mean corpuscular hemoglobin concentration (MCHC), 327–328, **329**
 Measles, 364, **369**, **466**
 Medical laboratory technician, 3
 Medical technologist, 3
 Melanoma, 97
 MELAS syndrome, 295
 MEN. *See* Multiple endocrine neoplasia
 Meningitis, 96, 99–100, **180**, 487
 aseptic, **94–95**, 99
 bacterial, **94–95**, 99, 101–103, 475, 484, 506
 chemical, 99
 cryptococcal, 101
 fungal, 99, 101, 103–104, 475
 rapid diagnosis, 475
 tuberculous, **94–95**, 98–99, 101–103
 Meningoencephalitis, 100
 amebic, 104, 485
 viral, 100–101
 Menstrual cycle, 546
 MERRF syndrome, 295
 Mesenteric venous thrombosis, 115
 Mesothelioma, **180**
 Metabolic acidosis, 29, 37–39, **38**, **73**
 Metabolic alkalosis, 29, **32**, 37–38, **38**, **73**, **73**
 Metabolic disease. *See* Inherited metabolic disease
 Metabolic screening, 297–299
 Metals
 analytical methods, 252
 toxicity, 252
 Metanephrines, urine, 168
 Methanol, **247**
 Methyl dopa, **177**
 Methylene blue stain, 485
 Methylmalonic acid, urine, 338
 Metoclopramide, **177**
 Metyrapone test, 163
 MGUS. *See* Monoclonal gammopathy of undetermined significance
 Microalbuminuria, 77, 189
 Microbiological examination
 peritoneal effusion, 116
 serous effusions, 111–112
 Microcrystals, synovial fluid, 119
 β_2 -Microglobulin, **128**, 130
 HIV disease, 469–470, **469**
 Microhemagglutination test, *Treponema pallidum* antibodies, 502–503
 Microscopic analysis, syphilis, 501
 Microscopic examination
 infectious disease, 482–487
 synovial fluid, 119
 urine, **90**
 Microsporidia, 479
 Midstream clean-catch urine specimen, 69, **69**, 476
 Migraine, 31
 Miller-Dieker syndrome, 306
 Mineralocorticoids, 162
 Minimal change disease, 132
 Minimal myocardial damage, 237
 Mitochondrial DNA disorders, 295
 Mitochondrial myopathy with encephalopathy, 295
 Mixed B and T lymphocyte defects, 458, **459**
 Mixed connective tissue disease (MCTD), **449**, **451**, 452
 Molecular diagnostics, 313–324
 amplification techniques, 315–316, **316**
 analytical techniques, 314–318
 applications, 319–324, **320**
 background, 314, 518–519
 bacterial infections, 519–520
 cancer testing, **320**, 321–323
 fungal infections, 521

- genetic disease testing, 319–320, **320**
 identity testing, **320**, 324
 infectious disease, **320**, 323, 517–525
 in situ hybridization, 317
 limitations, 524–525
 mutation analysis, 317
 quality control, 318
 Southern blot, 314–315
 standardization, 524
 viral infections, 521–524
- Mollaret cells, 99
- Moniliasis, 49
- Monoclonal gammopathy, 76, 133, 381, 382, **383**, **462**
- Monoclonal gammopathy of undetermined significance (MGUS), 126, 133, 382
- Monocytes, 368
 CD antigens, **373–374**
 differential leukocyte count, **359**
- Monocytopenia, **358**, 368, **368**
- Monocytosis, **358**, 368, **368**
- Moraxella catarrhalis*, 477, 487
- Morphine, 248
- Mosaic, **304**, 306
- Motility testing, wet mounts for, 484
- Mouth specimen, 479
- M-proteins, 124–126, 133, 264
- Multiple endocrine neoplasia (MEN), 201
 type 1, 51, 176, 191
 type 2a, 274, **320**, 323
 type 2b, **320**, 323
- Multiple fetuses, 283
- Multiple myeloma, 51, 76, 126, 130, 132–133, **263**, 264–265, 399
- Multiple sclerosis, **94–95**, 99–101, 127, 136
- Mumps, **369**, **542**
- Muscle cramps, 48
- Muscular dystrophy
 Becker, **320**
 Duchenne, **320**, 321
- Mutation analysis, 317, **320**, 321
- Myasthenia gravis, **450**
- Mycobacteria, 485
 Mycobacterium avium-intracellulare complex, 519
 Mycobacterium goodii, 519
 Mycobacterium kansasii, 519
 Mycobacterium tuberculosis. *See* Tuberculosis
 Mycoplasma hominis, 481
 Mycoplasma pneumoniae, 479
- Mycosis, superficial, 483
- Myelin basic protein, CSF, 101
- Myeloblasts, 376
- Myelodysplastic syndrome, 308, **309**, **327**, 332, 338, **339**, 377, **377**
- Myelofibrosis, **342**
- Myelofibrosis with myeloid metaplasia, 367, 378
- Myeloperoxidase deficiency, 464–465
- Myeloperoxidase slide test, **464**, 465
- Myelophthisic anemia, 342, **342**
- Myelophthisis, **364**
- Myeloproliferative disorder, **366–367**, 367, 378, **378**
- Myocardial infarction, **107**
 acute
 spectrum, 236
 unstable angina and, 237
 assessment, 235–244
 neutrophilia, 362
 risk stratification, 237
- Myocardial ischemia, 237–238
- Myocardial markers of injury, 235–244
 background, 236–238
 biochemical markers, 238–240
 creatinine kinase and lactate dehydrogenase isoenzymes, 238–239
 creatinine kinase isoforms, 239
 myoglobin, 239
 qualitative versus quantitative tests, 243–244
 rapid cardiac marker diagnostic protocol, 241–244, **242**
 troponins, 240
 utility of, 240–241
- Myocardial necrosis, 237–238
- Myocarditis, viral, 240
- Myoglobin, myocardial injury, 239
- Myoglobinuria, 80
- Myotonic dystrophy, 186
- ## N
- Nasopharyngeal specimen, 477
- NBT assay. *See* Nitroblue tetrazolium assay
- Neisseria*, 543
 Neisseria gonorrhoeae, 477, 480
 Neisseria meningitidis, 475, 477, 487, 506
- Neonatal screening, 534–535
 cystic fibrosis, 535
- Neonate. *See* Pediatric patient
- Neopterin, 469–470, **469**
- Nephelometry, serum proteins, 127
- Nephritis
 interstitial, 85, 87
 lupus, 76, 84
- Nephropathy, diabetic, 76, 189
- Nephrosclerosis, 76, 86
- Nephrosis, congenital, 284
- Nephrotic syndrome, 27, 76, 88, **106**, **112**, **131**, 132, 135, **144**, 189, 224, **407**, 414
- Nephrotoxicity, 252
- Nesidioblastosis, **191**, 193
- Neural network, 23
- Neural tube defect, 266, 284, 288
- Neuroblastoma, **263**, 276–278, 323
- Neuron-specific enolase (NSE), **263**, 276
- Neuropathy
 diabetic, 100
 peripheral, 252
- Neurosyphilis, **94–95**, 101
- Neutropenia, **358**, 363–364, **364**, 435, 463
 alloimmune neonatal, 435
 autoimmune, 435
 pathologic, 364
 physiologic, 363
- Neutrophil(s), 359–365
 antimicrobial function assay, 464
 band forms, **359**, 360
 bone marrow, 359–360
 CD antigens, **374**
 chemotactic ability, 465
 CSF, 99
 differential leukocyte count, **359**
 kinetics, 359–360
 leukemoid reaction, **361**, 362–363
 oxidative function test, 464, **464**
 peripheral blood, 360
 peritoneal effusion, 114
 qualitative genetic abnormalities, 365
 segmented, **359**, 360
 surface antigens, 465

tissue, 360
 Neutrophilia, **358**, 361–362, **361**
 inflammatory response, 362
 pathologic, **361**, 362
 physiologic, 361, **361**
 Nezelof's syndrome, **459**
 Nicotinic acid, 185
 Nitrite test, urine, 82–83
 Nitroblue tetrazolium (NBT) assay, 464
 NK cells, **373–374**
 NMP. *See* Nuclear matrix proteins
Nocardia, 486
 Noncompliance, monitoring, 257
 Nonglucose reducing substances, urine, 79, **79**
 Non-Hodgkin lymphoma, 378–380
 peripheral B-cell, **379**
 peripheral T-cell, **379**
 Nontreponemal antibody test, syphilis, 501
 Non-tropical sprue, 277
 Noonan's syndrome, **542**
 Nordoxepin, **259**
 Norfluoxetine, **259**
 Nortriptyline, **259**
 Norwalk virus, **493**
 NSE. *See* Neuron-specific enolase
 N-telopeptide, **53**
 Nuclear matrix proteins (NMP), 279
 Nucleic acid probes, 518
 Nucleic acid sequence-based amplification, 316, **316**
 Nucleolar antibodies, **449**
 5'-Nucleotidase, 276

O

Oat cell carcinoma, 180
 O-bands, 127, 136
 Obesity, **144**, **226**, **407**
 Odor, urine, 72, **72**
 Oligospermia, 540, **542**
 Oliguria, 64, 68, 75
 Oncofetal antigens, 262
 Opiates, 248
 Oral contraceptives, **407**, 410, 412, 414
 Organic acids, urine, 299
 Organic phosphate, 42
 Orthopedic surgery, **407**
 Osmolal gap, **247**, **247**
 Osmolality
 blood, 63–64, 75
 plasma, 63–64
 urine, 63–64, 74–75, 179–180
 Osteoarthropathy, hypertrophic, **117**
 Osteocalcin, **53**
 Osteochondritis dissecans, **117**
 Osteochondromatosis, **117**
 Osteomalacia, 48–49
 Osteoporosis, 52–53, **117**
 Otitis media, 477
 Oval fat bodies, urine, 88
 Ovarian cancer, **263**, 267–268, 274, **320**
 Ovarian failure, 546
 Ovarian tumor, 276
 Overhydration, **131**
 Ovulation, 175
 Oxidative function test, neutrophils, 464, **464**
 Oxygen

dissolved, 33
 partial pressure
 blood, 33, 35, **36**
 CSF, 102
 Oxygen saturation, 35–36, **36**

P

p24 antigen capture assay, HIV antibody, 467–468
 p53 gene, 323
 PABA test. *See* Para-aminobenzoic acid test
 Packed red blood cells, 437–438
 Paget's disease, 52–53
 PAI-1 defects, **407**
 Pancreatic cancer, **180**, 203, 207, **263**, 268, **361**, 362
 Pancreatic disease, **78**, 206–208, 215
 Pancreatic function, exocrine. *See* Exocrine pancreas function tests
 Pancreatitis, 110, **112**, 145–146, **222**
 acute, **48**, 50, 115, 204–207
 chronic, 203, 207, 217
 Pancytopenia, **358**
 PAP. *See* Prostatic acid phosphatase
 Papillitis, necrotizing, 85
 Para-aminobenzoic acid (PABA) test, 205
 Paracetamol, 205
 Parainfluenza virus, 478, **493**, **495**
 Paraldehyde, **247**
 Paraproteinemia, 46, **131**, 133
 Paraproteinuria, 134
 Parasitic infections, immunologic tests, 508
 Parathyroid hormone (PTH), 43–44, **43**, **46**, 47–52
 Parathyroid hormone-related protein (PTHrP), 51, **263**, 264–265
 Paratyphoid, 364
 Parotitis, mumps, 206
 Paroxetine, **259**
 Paroxysmal cold hemoglobinuria, **352**
 Paroxysmal nocturnal hemoglobinuria, **344**, **352**, 354
 Partial thromboplastin time (PTT), 387, 391–392
 Parvovirus B19, 523
 Paternity testing
 blood banks, 436
 molecular diagnostics, 324
 RBC antigens, 436
 PCP. *See* Phencyclidine
 PCR. *See* Polymerase chain reaction
 Pediatric patient, 527–536
 background, 528
 blood collection, 528–532, **529–530**
 HIV disease, 468
 hypoglycemia, 192–193
 neonatal screening, 534–535
 reference ranges, 532–534
 Pentamidine, **191**
 Pentosuria, 79
 Peptic ulcer disease, 196–200, 202
 Pericardial effusion
 causes, 106, **107**
 cell counts and cytomorphology, 109
 chemistry, 109–110
 diagnosis of infectious disease, 482
 enzymes, 110
 glucose, 110
 immunologic studies, 111
 laboratory assays, 109
 lactate dehydrogenase, 109
 lipids, 110

- microbiologic examination, 111–112
- pH, 111
- protein, 109
- specimen collection, 108
- tests performed on, **107**
- tumor markers, 111
- visual inspection, 108, **108**
- Pericardial fluid, 106–112
 - background, 106–107
- Pericarditis, tuberculous, 110
- Peritoneal effusion
 - causes, **112**
 - cell counts and cytomorphology, 114
 - chemistry determinations, 114–115
 - diagnosis of infectious disease, 482
 - enzymes, 115
 - glucose, 114–115
 - laboratory assays, 114
 - lactate dehydrogenase, 114
 - lipids, 115
 - microbiologic examination, 116
 - pH and lactate, 115
 - protein, 114
 - specimen collection, 113
 - tests performed on, **107**
 - tumor markers, 115
 - visual inspection, 113
- Peritoneal fluid, 112–116
 - background, 112
- Peritoneal lavage, 113
- Peritonitis, 206
 - spontaneous bacterial, 114–116
 - tuberculous, 115–116
- Pernicious anemia, 201, 215, 337, **450**
- Peroral mucosal biopsy, 214
- Persistence of fetal hemoglobin, 430
- Pertussis, **369**, 477, 486, 520
- PG-Numeric, 292
- pH
 - blood, 33–35, **36**, 37
 - CSF, 102
 - peritoneal effusion, 115
 - serous effusions, 110–111
 - urine, 72–73, **73**
- Phagocytic cell defects, 458, **459–460**, 463–465, **464**
- Pharyngitis
 - gonococcal, 477
 - streptococcal, 478
- pH electrode, 35
- Phenazopyridine, 83, 223
- Phencyclidine (PCP), 248–249
- Phenobarbital, **258**
- Phenothiazines, **180**
- Phenotype, RBC, 427
- Phenylbutazone, **340**, **364**
- Phenylketonuria (PKU), **72**, 299, 321, 534
- Phenytol, 228, **258**
- Pheochromocytoma, **78**, 168, **263**, 278
- Philadelphia chromosome, 322, 378
- Phosphorus/phosphate, 42, 48, 52
 - dietary, 42
 - inorganic, 42
 - organic, 42
 - tests for phosphorus metabolism, 43, **43**
- Physician, laboratory and, 1–7
- Pituitary function, 171–180. *See also specific pituitary hormones*
 - background, 172–174
 - regulation by hypothalamus, 172, **172**
- Pituitary tumor, 157, **158**, 174–178, **177**
- PKU. *See* Phenylketonuria
- Plasma cell(s), **371**
 - CD antigens, **374**
- Plasma cell dyscrasias, 124
- Plasma cell myeloma, **342**, 381–382, 384
- Plasmacytoma, 51
- Plasma proteins, 47
- Plasmin, 399–400, 402
- Plasminogen, 399
 - deficiency, 415
- Plasminogen activators, 399, 417–418
- Platelet(s), 386
 - antibody detection, 435
 - antigen typing, 434
 - evaluation of bleeding patient, 390–392
- Platelet count, 390–391, 406
- Platelet disorders, 390–391
- Platelet plug, 386
- Platelet-rich microthrombi, 403–404
- Platelet transfusion
 - apheresis platelets, 439
 - platelets pooled from donors of whole blood, 438
- Pleocytosis, 99
- Pleural effusion, 479
 - causes, 106, **106**
 - cell counts and cytomorphology, 109
 - chemistry, 109–110
 - diagnosis of infectious disease, 482
 - enzymes, 110
 - exudate, **106–107**
 - glucose, 110
 - immunologic studies, 111
 - laboratory assays, 109
 - lactate dehydrogenase, 109
 - lipids, 110
 - microbiologic examination, 111–112
 - pH, 110–111
 - protein, 109
 - specimen collection, 108
 - tests performed on, **107**
 - transudate, **106–107**
 - tumor markers, 111
 - visual inspection, 108, **108**
- Pleural fluid, 106–112
 - background, 106–107
- Pneumocystis carinii*, 485
- Pneumonia, **180**
 - pneumococcal, 478, 484
- Point of care testing, 4
- Polyarteritis nodosa, **455**
- Polyclonal gammopathy, 382, **383**
- Polycystic kidney disease, 64, 76, **84**, **320**
- Polycystic ovary disease, **177**, **547**
- Polycythemia, 326, 354–355, **407**
 - primary, 354, **355**, 367, **378**
 - secondary, 355, **355**
- Polycythemia vera. *See* Polycythemia, primary
- Polydipsia, 78, 179
 - psychogenic, 27, **68**
- Polyglandular autoimmune syndromes, 163
- Polymerase chain reaction (PCR), 314–316, **316**, 518–525
 - quality control, 318
 - reverse transcriptase, 315, **316**, 322
- Polymerase chain reaction (PCR) test
 - Helicobacter pylori*, 198–199

- HIV antibody, 468
 Polyneuritis, 100
 Polyuria, 68, **68**, 75, 78, 179
 Porcine factor VIII concentrate, 442
 Porphyria, 333
 acute intermittent, **180**
 Postanalytical error, 21
 Postinfarction syndrome, **107**
 Post-phlebotic syndrome, **407**
 Potassium, 28, **33**, 166
 Potassium electrode, 30
 Potassium hydroxide preparation, 483
 Poxvirus, 485–486
 Prader-Willi syndrome, 306
 Prealbumin, 128, **128**
 Preanalytical error, 20, **22–23**
 Predictive value of test, 5, 13–16, **15**
 negative, 14
 positive, 14–15
 Preeclampsia, 76
 Pregnancy, 282
 abnormal bleeding following missed menses, **291**
 alpha-fetoprotein, 282, **283**, 284, 288
 aplastic anemia and, **340**
 ectopic, 283, 285, 290
 estriol, 282, **283**, 284–285
 human chorionic gonadotropin, 273, 282, **283**, 286–288, 290
 progesterone, 285, 290
 Pregnancy test, 286–288
 home tests, 287
 Prekallikrein deficiency, 392
 Prenatal testing
 ABO and Rh grouping and antibody screen, 429
 anatomic and chromosomal defects, 288, **289**, 306
 background, 282
 fetal lung maturity, 290–292
 Preoperative blood deposit, 444
 Prevalence of disease, 5, **15**
 Primary amebic meningoencephalitis, 99, 104, 475
 Primers, 315
 Primidone, **258**
 Procainamide, **258**
 Procollagen-1 extension peptides, **53**
 Progesterone, 546, **546**
 in pregnancy, 285, 290
 Progressive systemic sclerosis. *See* Scleroderma
 Prolactin, 172–173, **172**, 175, 546, **546**
 deficiency, 174
 Prolactinoma, 177, **177**, 542, **547**
 Prostaglandins, **366**
 Prostate cancer, 50, **180**, **263**, 269–271, **272**
 Prostate-specific antigen (PSA), 13–16, **16**, 270–271, **272**
 density determination, 271
 free PSA to total PSA ratio, 271
 rate of change in serum concentration, 271
 Prostatic acid phosphatase (PAP), **263**, 269–270
 Prostatic infarction, 269
 Prostatitis, 269
 Protamine sulfate test, 402
 Protein
 CSF, 100–101
 peritoneal effusion, 114
 serous effusions, 109
 serum. *See* Serum proteins
 urine, 75–77
 Protein C, 399, 407–411. *See also* Activated protein C resistance
 congenital deficiency, 409
 mechanism of action, **408**
 Protein S, 399, 411–412
 acquired deficiency, 412
 congenital deficiency, 411–412
 defects, **407**
 Proteinuria, 75–77, 87, **131**, 134–135
 functional, 76
 glomerular, 134–135
 postrenal, 135
 postural, 76
 selective, 134
 transient, 76
 tubular, **131**, 135
 Protein wasting, **131**
 Prothrombin complex concentrate, 441
 Prothrombin deficiency, 392
 Prothrombin fragment 1 + 2 assay, 406
 Prothrombin time (PT), 223–224, 387, 391–392
 Proto-oncogene analysis, 323
 Protriptyline, **259**
 Prozone phenomenon, 501
 PSA. *See* Prostate-specific antigen
 Pseudochylous effusion, 108, **108**, 110
 Pseudocyst, pancreatic, 115
 Pseudogout, **117**, 119
 Pseudohyperkalemia, 28
 Pseudohypoparathyroidism, **48**, 49, 52
 Pseudo-von Willebrand's disease, 396
 Psychotropic drugs, **177**
 PT. *See* Prothrombin time
 PTH. *See* Parathyroid hormone
 PTHrP. *See* Parathyroid hormone-related protein
 PTT. *See* Partial thromboplastin time
 Pulmonary embolus, **106**, 409, 411, 414–416
 Pulmonary hyaline membranes, 404
 Pulmonary infarction, 108, **108**, 362
 Pulsed-field gel electrophoresis, 518
 P50 value, 36
 Pyelonephritis, 76, 85, 87
 Pyospermia, 544
 Pyridinoline, **53**
 Pyroptokilocytosis, hereditary, 349
 Pyuria, **72**, 82–84
- ## Q
- Q-beta replicase, 316, **316**
 Quality control, molecular diagnostics, 318
 Quinidine, **258**
- ## R
- Rabies, 486, **493**
 Radioimmunoassay (RIA)
 drug screen, 249
 histoplasmosis, 507
 parathyroid hormone-related protein, 265
 Random error, 20–21
 Random urine specimen, 69, **69**
 Rapid cardiac marker diagnostic protocol, 241–244, **242**
 Rapid plasma reagin (RPR) test, 502
 Rapid urease test, 199

- ras* gene, 323
 Rate nephelometry, complement fractions, 465
 RBC. *See* Red blood cell(s)
 RDW. *See* Red cell distribution width
 Receiver-operator characteristic (ROC) curve, 17–18, **18**
 Recombinant immunoblot assay (RIBA), hepatitis C virus, 230
 Red blood cell(s) (RBC)
 accelerated destruction, 344–354
 cell size, 326–327, **329**
 chromium-labeled, half-life disappearance time, 347, **347**
 elution studies, 428–429
 impaired production, 332–343
 phenotyping, 427
 production and destruction, 329–331
 size variability, 328, **329**
 surface antigens, 422
 transfusion
 cells in additive solution, 438
 cells in CPDA-1 preservative/anticoagulant, 437–438
 Red blood cell (RBC) antibody
 identification, 424–425
 screening, 424
 Red blood cell (RBC) enzymopathies, 351
 Red blood cell (RBC) membrane abnormalities, **344**, 348–349
 Red blood cell (RBC) precursors, decreased, 340–343
 Red cell distribution width (RDW), 328, **329**
 Red cell indices, 326–329, **329**
 Reed-Sternberg cells, **374**, 379
 Reference interval, 18–20
 age-related, 19, 532–534
 gender-specific, 19
 individual-specific, 20
 population-based, 20
 Refractometer, 63, 74
 Refractometry, serum proteins, 122
 Refractory anemia, **377**
 Reiter's syndrome, **117**
 REMEDi Drug Profiling System, 251
 Remnant removal disease, 147
 Renal cell carcinoma, 355, **355**
 Renal clearance, 56, **57**, 59
 Renal concentrating capacity, 63–64
 Renal diluting capacity, 65
 Renal disease
 autoimmune, **455**
 hypocalcemia, 50
 renal function tests, 55–65
 urinalysis. *See* Urinalysis
 Renal failure, 27–28, 38, 48, 189, 202, 257
 anemia, **327**, 343
 chronic, 47, **68**, **177**, 367, **367**
 hypercalcemia, 50
 hyperlipidemia, **144**
 hyperphosphatemia, 52
 Renal failure casts, 85
 Renal function tests, 55–65
 background, 56–59
 blood urea nitrogen, 62
 creatinine, 59–62
 renal concentrating capacity, 63–64
 renal diluting capacity, 65
 Renal threshold for glucose, 78
 Renal transplant, 31, 85
 Renal tubular acidosis, 39, 73
 Renal tubular disease, 74, 76, **78**, 85
 Renal vein obstruction, 76
 Renin, 167
 Renin-angiotensin system, 162
 Reovirus, **493**
 Reproductive hormones
 in female, 546, **546**
 in male, 540, **540**
 Reptilase time, 405
 Reserpine, **177**
 Respiratory acidosis, 37, **38**, 39, **73**
 Respiratory alkalosis, 37, **38**, 39, **73**
 Respiratory syncytial virus, 478, **493**, **495**
 Respiratory tract specimen
 diagnosis of infectious disease, 477–479
 diagnosis of viral disease, **493**
 Restriction endonuclease, 314
 Restriction fragment length polymorphism (RFLP), 319, 518
 Retained gastric antrum, 202
 Reticular dysgenesis, **459**
 Reticulocyte(s), “shift,” 345
 Reticulocyte count, 329–331, **329**, **331**, 348
 Reticulocyte production index (RPI), 330, **330**
 Reticulocytosis, 338
 Retinoblastoma, **320**, 323
 Retinol-binding protein, 128, **128**
 Retrograde ejaculation, 539, **542**
 RF. *See* Rheumatoid factor
 RFLP. *See* Restriction fragment length polymorphism
 Rhabdomyolysis, 50, 61
 Rhabdomyosarcoma, alveolar, **320**
 Rheumatic fever, 505–506
 Rheumatoid arthritis, 111, **117**, 362, 453
 Rheumatoid factor (RF), 111, 453
 Rh immune globulin, 442
 evaluation of therapy, 430
 Rhinorrhea, CSF, 100
 Rhinovirus, **493**, **495**
 Rh typing, 423, 429
 RIA. *See* Radioimmunoassay
 RIBA. *See* Recombinant immunoblot assay
 Rickets, 48
 vitamin D-resistant, 49
 Risk stratification, myocardial infarction, 237
 Ristocetin cofactor activity, 395–396
 Robotic laboratory, 4
 ROC curve. *See* Receiver-operator characteristic curve
 Rocky Mountain spotted fever, **368**
 Rosebud.
 Roseola, **369**
 Rosette test, 430
 Rotavirus, 479, **493**
 Rotor syndrome, 221, **222**
 Routine order, 5
 RPI. *See* Reticulocyte production index
 RPR test. *See* Rapid plasma reagin test
 Rubella, 185, **369**, **466**
- S**
 SAAG. *See* Serum-ascites albumin gradient
 Sabin-Feldman dye test, 508
 St. Louis encephalitis, **493**
 Salicylates, 38, 134, **191**, **247**, **258**, 391
Salmonella, 479
 Sarcoidosis, 51, 99, 101, 226, 265, 268, **368**, **466**
 Schilling test, 215, 337
Schistosoma haematobium, 90
 SCL-70 antibodies, **449**

- Scleroderma, **117**, 240, **449**, **451**
- Screening tests, 2, 11
 metabolic screening, 297–299
 neonatal screening, 534–535
- Secretin, 203
- Secretin cholecystokinin test, 205
- Sedative-induced acidosis, 39
- Sediment constituents, urine, 83–88
- Selective IgA deficiency, 458, **459**, 461, **462**
- Semen analysis, 539, **539**
- Seminoma, 276
- Sensitivity of test, 5, 13–16, **16**
- Serologic tests. *See also* Immunologic tests
Helicobacter pylori, 196–197
 viral infections, **494**, 497
- Serotonin, 276–277
- Serous effusion, 105–116
- Sertraline, **259**
- Serum-ascites albumin gradient (SAAG), 112
- Serum protein(s), 121–136
 analytical methods, 122
 background, 122
 isoelectric focusing, 126–127
 nephelometry, 127
 properties of selected proteins, 128–134, **128**
 quantification, 122
- Serum protein electrophoresis, 123–124, **123**, 382, **383**
 immunoelectrophoresis, 126
 immunofixation electrophoresis, 124–126, **125**
 in various disease states, **131**
- Severe combined immunodeficiency, 458, **459**
- Sex chromosome abnormalities, 305–306, **305**
- Sexually transmitted disease, 481
- Shake test, surfactant in amniotic fluid, 292
- Sheehan's syndrome, 174
- Shell vial culture, 496
- Shigella*, 479
- Short tandem repeats (STR), 319, 324
- Shwachman syndrome, 364
- SIADH. *See* Syndrome of inappropriate ADH secretion
- Sialoprotein, bone, **53**
- Sick-euthyroid patient, 157
- Sickle cell anemia, 64, 127, 321, 349–350, 534
- “Sickle prep,” 350
- Sideroblast(s), 343
- Sideroblastic anemia, **327**
- Silent ischemia, 236, 238
- Single-strand conformation polymorphism (SSCP) analysis, 317
- Sipple's syndrome, 274
- Sjögren's syndrome, **449**, **451**, 452
- SLE. *See* Systemic lupus erythematosus
- Small bowel resection, 202
- Small intestinal biopsy, lactase deficiency, 216
- Smooth muscle antibodies, 231–232
- Sodium, 27–28, **33**, 180
- Sodium electrode, 30
- Solubility test, hemoglobin S, 350
- Soluble fibrin monomer, 402
- Somatostatin, 172, **172**
- Somatotropes, 173
- Sorbitol, **247**
- Southern blot, 314–315
- Specific gravity, urine, 63, 73–74
- Specificity of test, 5, 13–16, **16**
- Specimen
 infectious disease diagnosis, 472–473
 viral disease diagnosis, 492–493, **493**
- Specimen transport, 473, 492–493
- Spermatogenic failure, 540
- Sperm motility, 540
- Sperm penetration assay, 543
- Spherocytosis, hereditary, 345, 349
- Spinal cord tumor, **94–95**, 100
- Spinobulbar muscular atrophy, 321
- Spinocerebellar ataxia, 321
- Splenectomy, 367, **367**, **466**
- Splenomegaly, 354
- Spontaneous bacterial peritonitis, 114–116
- Spontaneous paroxysmal myoglobinuria, 80
- Sputum specimen, 478–479
- SSCP analysis. *See* Single-strand conformation polymorphism analysis
- Stained smear, 484–486
- Staining, cytogenetic techniques, 302
- Staphylococcus*, 477, 487
- Starvation, 82
- STAT order, 5
- Steatonecrosis, alcoholic, 224
- Steatorrhea, 206–207, 212–213, 397
- Sterile urine specimen, 69
- Steroid therapy, **355**
- Sticky platelet syndrome, **407**, 417
- Stomatocytosis, hereditary, 349
- Stool drainage, 483
- Storage disease, **342**
- STR. *See* Short tandem repeats
- Streptococcal disease
 antideoxyribonuclease B antibody test, 505
 antistreptolysin O tests, 505
 immunologic tests, 504–506
 streptozyme test, 505–506
- Streptococci, group B, 487, 506
- Streptococcus milleri* group, 487
- Streptococcus pneumoniae*, 477, 487
- Streptococcus pyogenes*, 477–478, 487, 506
- Streptokinase, 418
- Streptozyme test, 505–506
- Strychnine, **247**
- Subacute sclerosing panencephalitis, 99, 136
- Subarachnoid block, 100
- Subarachnoid hemorrhage, **94–95**, 96–97, **97**, 100–101
- Subdural hematoma, 100
- Substance abuse testing
 analytical methods, 249–251
 background, 246–247
 drug screens and analysis, 248–249
- Sulfonamides, 205, **364**
- Sulfonylureas, **191**, 192
- Suprapubic aspiration of urine, 476
- Surfactant, amniotic fluid, 286, **287**, 291–292
- Sweat chloride, 208, 535–536
- Syndrome of inappropriate ADH secretion (SIADH), 27, 180, **180**
- Synovial fluid
 background, 116–117, **117**
 diagnosis of infectious disease, 482
 examination, 117–120, **118**
 gross examination, 118–119, **118**
 indications for analysis, 116
 light microscopic examination, 119
- Synovioma, **117**
- Synovitis, pigmented villonodular, **117**
- Syphilis, 136, **368–369**, 480–481, 483
 congenital, 503
 fluorescent treponemal antibody absorption test, 503
 immunologic tests, 500–503, **504**

- meningovascular, 99
- microhemagglutination test for *T. pallidum* antibodies, 502–503
- microscopic analysis, 501
- neurovascular, 100
- nontreponemal antibody test, 501
- rapid plasma reagin test, 502
- testing of donor blood, 434
- treponemal antibody tests, 502
- VDRL test, 501
- Systematic error, 20–21
- Systemic lupus erythematosus (SLE), 111, **117**, 132, 134, 268, 352, 416, 448–450, **449**, **451**, 452

T

- Tamm-Horsfall protein, 76, 86
- Target cells, 353
- Target concentration, 257
- Tartrate-resistant acid phosphatase (TRAP), **53**
- τ -protein, 135
- T-cell receptor locus, 322
- TDx FLM assay, 292
- 10% tumor. *See* Pheochromocytoma
- Teratospermia, 540
- Terminal ileal function, 215–216
- Testicular biopsy, evaluation of azoospermia, 540
- Testicular cancer, **263**, 266
- Testosterone, **172**, 175, **540**, 541–542
- Tetany, 47–48
- Tetracycline, 83
- Thalassemia minor, **327**, 328, 333–334, **334**
 - α -thalassemia minor, 334
 - β -thalassemia minor, 334
- Thalassemia syndromes, 350–351
- Thalassemia trait. *See* Thalassemia minor
- Thayer-Martin agar, 480
- Theophylline, **259**
- Therapeutic drug monitoring, 255–260
 - applications, 256–258, **258–259**
 - background, 256
 - commonly monitored drugs, **258–259**
 - guidelines, 259–260
- Thermal amplitude study, cold agglutinins, 433
- Thiazide diuretics, **51**, 185
- Thin-layer chromatography (TLC), drug screen, 250–251
- Thoracic duct disruption, **108**, 110
- Throat culture, 477–478
- Throat specimen, 477–478
- Thrombin, 402
- Thrombin-antithrombin complex, 406
- Thrombocytopenia, essential, **378**, 412
- Thrombocytopenia, 390–391
 - neonatal alloimmune, 434
- Thrombocytopenic purpura
 - immune, 435
 - thrombotic, **353**, 403
- Thrombolytic therapy, 243, 417–418
- Thrombomodulin, 407
- Thrombophilia, hereditary, 413
- Thrombophlebitis, superficial, 409, 411
- Thrombosis, 397–399
 - background, 386
 - etiology, **407**
 - hypercoagulable states, 406–418
- Thymocytes, **373**
- Thymoma, 164, **180**, **340**
- Thyroid cancer, **263**, 272–274, 276, **320**, 323
- Thyroid function, 153–159
 - algorithm for thyroid disorders, **12**
 - background, 154
 - caveats for thyroid testing, 157–158, **158**
 - differential diagnosis of thyroid disorders, 157
 - monitoring thyroid replacement therapy, 158–159
 - physiology, 154–155
 - testing strategies, 155–157, **156–157**
- Thyroiditis
 - autoimmune, 273
 - Hashimoto's, 49, 273, **450**
 - subacute, **450**
- Thyroid replacement therapy, 158–159
- Thyroid-stimulating hormone (TSH), 155–158, **155–156**, 172–173, **172**, 175
 - deficiency, 174
- Thyroid storm, **361**
- Thyrototoxicosis, **51**
- Thyrotropes, 173
- Thyrotropin. *See* Thyroid-stimulating hormone
- Thyrotropin-releasing hormone (TRH), 157, 172, **172**, **177**
- Thyrotropin-secreting tumor, 178
- Thyroxine, 158–159, **172**
 - free (FT_4), 154–155, **155**, 157–158, 175
 - overdose, 157
- TIBC. *See* Total iron-binding capacity
- Tick fever, **493**
- Timed urine collection, 69, **69**
- Tissue
 - diagnosis of infectious disease, 482
 - specimen for cytogenetic studies, 310
- Tissue factor, 387
- Tissue plasminogen activator, **407**, 417–418
- TLC. *See* Thin-layer chromatography
- T lymphocytes, 370–373, **373–374**
 - antigens, 463
 - antigens associated with, **371**
 - CD4, 469, **469**
 - CD8, 469, **469**
 - CD antigens, **373**
 - clonality status, **382**
 - defects, 458, **459**, 461–463, **463**
 - in vitro function test, 463
 - quantitation, 463, **463**
- Tn. *See* Troponin
- Tobramycin, **258**
- Toluene, **247**
- Topiramate, **258**
- Total iron-binding capacity (TIBC), 333–334, **336**
- Total serum iron (TSI), 333–334, **336**
- Toxic granulation, neutrophils, 360, **361**
- Toxicology
 - analytical methods, 249–251
 - background, 246–247
 - drug screens and analysis, 248–249
- Toxi-Lab, 250
- Toxoplasmosis, 101, **369**, 508, 534–535
- Transcortin, 162
- Transcription mediated amplification, 316, **316**
- Transferrin, **128**, 130, 135, 333
- Transferrin saturation, 333–334, **336**
- Transfusion, massive, **48**, 50
- Transfusion medicine
 - ABO grouping, 422–423, 429
 - antibody screening, 424
 - background, 422

- blood components for transfusion, 437–444
 cold agglutinins, 432–433
 direct Coombs' test, 427–428
 donor blood testing, 433–434
 evaluation of Rh immune globulin therapy, 430
 granulocyte antigen/antibody tests, 435
 "group, screen, hold," 425
 histocompatibility typing, 436
 paternity testing, 436
 platelet antibody detection, 435
 platelet antigen typing, 434
 prenatal screening, 429
 RBC antibody identification, 424–425
 RBC elution studies, 428–429
 RBC phenotyping, 427
 Rh typing, 423, 429
 transfusion reactions, **352**, **361**, 431
 type and crossmatch, 426–427
 umbilical cord blood testing, 429–430
 warm autoimmune hemolytic anemia, 431–432
- Translocation, **304**, 322
 Transrectal ultrasonography (TRUS), 271, **272**
 Transudate, 106, 108–109, **108**
 TRAP. *See* Tartrate-resistant acid phosphatase
 Trazodone, **259**
 Treatment monitoring, 3
 Treponemal antibody tests, 502
Treponema pallidum. *See* Syphilis
 TRH. *See* Thyrotropin-releasing hormone
 Trichloroethane, **247**
Trichomonas vaginalis, 481, 484
 Tricyclic antidepressants, **180**, 248
 Triglycerides, 143–144
 Triiodothyronine, 157, **172**
 free (fT₃), 154
 Trimipramine, **259**
 Trinucleotide repeat expansion, 321
¹⁴C-Triolein breath test, 212
 Tripelennamine, **340**
 Triple bolus test, 175
 Trisomy 13, **305**
 Trisomy 18, 283–285, 288, 305, **305**
 Trisomy 21, 186, 266, 282, 284–285, 288, 305, **305**
 Troponin I (TnI), 237, 240, 243
 Troponin T (TnT), 237, 240
 TRUS. *See* Transrectal ultrasonography
 Trypanosomiasis, 136
 Trypsin, serum immunoreactive, 207–208
 TSH. *See* Thyroid-stimulating hormone
 TSI. *See* Total serum iron
 Tuberculosis, **107–108**, 109–111, **112**, 113, 163, **180**, 210, 226, 268, 368, **368–369**, 485, **547**
 molecular diagnostics, 518
 renal, 84–85
 Tularemia, 364
 Tumor cells, urine, 91
 Tumor lysis syndrome, 50
 Tumor markers, 261–279. *See also specific markers*
 background, 262–264, **263**
 ideal, 263–264
 new markers, 279
 peritoneal effusion, 115
 serous effusions, 111
 Tumor osteomalacia, 49
 Tumor suppressor analysis, 323
 Turner's syndrome, **305**
 Type and crossmatch, 426–427
- "Type and screen," 425
 Typhoid, 364, 474
 Tyrosinemia, 535
- ## U
- UGF. *See* Urinary gonadotropin fragment
 Umbilical cord blood testing, 429–430
 Unstable angina, 236–237
 Uracil-*N*-glycosylase, 318
 Urea, 62
 Urea breath test, 197–198
Ureaplasma urealyticum, 481
 Uremia, **78**, **107**, 257, **361**, **466**
 Ureteral cancer, **180**
 Urethral specimen, 480
 Urethritis, 480–481, 484
 chlamydial, 84
 nongonococcal, 480–481
- Urinalysis, 67–91
 background, 68–69
 bile pigments, 81, **81**
 blood hemoglobin and related pigments, 80
 casts, 85–88, **86**
 cells, 84–85
 chemical characteristics, 75–83
 clarity of urine, 71, **72**
 color of urine, 71, **71**
 components of, **70**
 contaminants, 91
 crystals, 88, **89**
 diagnosis of infectious disease, 475–476
 drug screen, 248–249
 glucose and other sugars, 78–79, **78–79**
 ketones, 82
 leukocyte esterase test, 82–83
 lipids, 88
 microorganisms, 89–91, **90**
 nitrite test, 82–83
 odor of urine, 72, **72**
 osmolality, 63–64, 74–75, 179–180
 pH of urine, 72–73, **73**
 physical properties of urine, 71–75
 proteins, 75–77
 routine, 70, **70**
 sediment constituents, 83–88
 specific gravity of urine, 63, 73–74
 tumor cells, 91
- Urinary calculi, 84, **84**
 Urinary catheter, sampling, 476
 Urinary free cortisol test, 164–165
 Urinary gonadotropin fragment (UGF), 273–274
 Urinary tract disease, 80
 Urinary tract infection, 89, 223, 476, 484
 Urine culture, 90, 476
 Urine protein electrophoresis, **131**, 134–135
 Urine specimen
 changes at room temperature, **70**
 collection, 68–69, **69**
 Urine volume, 68
 Urobilin, 71
 Urobilinogen, 69
 fecal, 345, **347**
 urine, 81, **81**
 Urochrome, 71
 Uroerythrin, 71

Urokinase, 417–418

V

Vaginal secretions, 480
 Vaginitis, 481
 Vaginosis, bacterial, 481
 Valproic acid, **258**
 Vancomycin, **258**
 Vanillylmandelic acid (VMA), 168, **263**, 278
 Variable number of tandem repeats (VNTR), 319, 324
 Varicella, **369**, **466**
 Varicose veins, **407**
 Vasculitis, 99, 391, 454, **455**
 VDRL test, syphilis, 501
 Venlafaxine, **259**
 Venoms, **352**, 353, **361**
 Venous blood gases, 36, **36**
 Venous thrombosis, 409–412, 414–416
 Ventricular shunt infection, 99
Vibrio, 479, 484
 Vincent's angina, 479, 484
 Vincristine, **180**
 Viral inclusions, urine, 91
 Viral infections, 491–498. *See also specific viruses and viral diseases*
 antibody response, 497
 background, 492
 centrifugation culture, **494**, 496
 cultivation of virus, 494–496, **494–495**
 direct detection of viruses in specimen, **494**, 496
 electron microscopy and histopathology, **494**, 497
 immunologic tests, 509–514
 laboratory diagnosis, 494–497, **494**
 molecular diagnostics, 521–524
 serologic tests, **494**, 497
 specimen collection and transport, 492–493, **493**
 Viscosity, synovial fluid, 118–119, **118**
 Vitamin B₁₂
 deficiency, **327**, **331**, 336–338, **337**
 serum, 337, **337**
 Vitamin D, 44–45, **46**
 activation, 44–45
 deficiency, 45, 48–49, **48**, 52
 end-organ resistance, 48
 excess, 265
 metabolism, 49
 Vitamin K, 223–224, 387
 deficiency, 223–224, 397
 VLDL, 140–141, **140**
 VMA. *See* Vanillylmandelic acid
 VNTR. *See* Variable number of tandem repeats
 Volume depletion, serum proteins, 133
 Vomiting, 28, 38, 82, **361**
 von Willebrand's disease (vWD), 391, 394–396, **395**, 399
 acquired, 396
 platelet-type, 396
 von Willebrand's factor, 394
 vWD. *See* von Willebrand's disease

W

WAIHA. *See* Warm autoimmune hemolytic anemia
 Waldenström's macroglobulinemia, 76, 133, 264
 Warfarin, 412
 monitoring treatment, 417

Warm autoimmune hemolytic anemia (WAIHA), 431–432
 Water deprivation test, 64, 179
 Water diuresis, 75
 Waxy casts, urine, **86**, 87
 WB assay, HIV antibody, 467
 “Weak D test,” 423
 Wegener's granulomatosis, 454, **455**
 Western equine encephalitis, **493**
 Wet mount, 483–484
 Whipple's disease, 214, 277
 Whipple's triad, 190
 Whole blood, 437
 Wilms' tumor, 306, 396
 Wilson's disease, 129, 234
 Wiskott-Aldrich syndrome, **459**
 Wolf syndrome, 306
 Wounds, diagnosis of infectious disease, 482
 Wright's stain, 485

X

Xanthochromia, 97
 Xanthoma, 147
 D-Xylose absorption test, 212–213
¹⁴C-D-Xylose breath test, 214

Y

Yellow fever, 364, **493**
Yersinia, 479
 Yolk sac tumor, 233, 266

Z

Zidovudine, 338
 Ziehl-Neelsen stain, 485
 Zollinger-Ellison syndrome, 51, 201, 275
 Zwitterion, 127

